Surface antigens of *Plasmodium falciparum*-infected erythrocytes as immune targets and malaria vaccine candidates

Jo-Anne Chan · Freya J. I. Fowkes · James G. Beeson

Received: 10 December 2013 / Revised: 4 March 2014 / Accepted: 17 March 2014 / Published online: 2 April 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract Understanding the targets and mechanisms of human immunity to malaria caused by *Plasmodium falciparum* is crucial for advancing effective vaccines and developing tools for measuring immunity and exposure in populations. Acquired immunity to malaria predominantly targets the blood stage of infection when merozoites of *Plasmodium* spp. infect erythrocytes and replicate within them. During the intra-erythrocytic development of *P. falciparum*, numerous parasite-derived antigens are expressed on the surface of infected erythrocytes (IEs). These antigens enable *P. falciparum*-IEs to adhere in the vasculature and accumulate in multiple organs, which is a key process in the pathogenesis of disease. IE surface antigens, often referred to as variant surface antigens, are important targets of acquired protective immunity and include PfEMP1, RIFIN, STEVOR and SURFIN. These antigens are highly polymorphic and encoded by multigene families, which generate substantial antigenic diversity to mediate immune evasion. The most important immune target appears to be PfEMP1, which is a major ligand for vascular adhesion and sequestration of IEs. Studies are beginning to identify specific variants of PfEMP1 linked to disease pathogenesis that may be suitable for vaccine development, but overcoming antigenic diversity in PfEMP1 remains a major challenge. Much less is known about other surface antigens, or antigens on the surface of gametocyte-IEs, the effector mechanisms that mediate immunity, and how immunity is acquired and maintained over time; these are important topics for future research.

Keywords *Plasmodium falciparum* · Variant surface antigens · Antibodies · PfEMP1 · Malaria · Vaccines

Abbreviations

- ATS: Acidic terminal segment of PfEMP1
- CD36: Cluster of differentiation 36 receptor
- CIDR: Cysteine-rich interdomain regions
- CMI: Cell-mediated immunity
- CR1: Complement receptor 1
- CSA: Chondroitin sulphate A
- DBL: Duffy binding-like domain
- HA: Hyaluronic acid
- ICAM-1: Intercellular adhesion molecule 1
- IE: *P. falciparum* infected erythrocyte
- KAHRP: Knob-associated histidine-rich protein
- MAHRP1: Membrane-associated histidine-rich protein 1
- MC: Maurer’s clefts
- MESA: Mature infected erythrocyte surface antigen
- PfEMP1: *P. falciparum* erythrocyte membrane protein 1
- PIMC-2TM: *P. falciparum* Maurer’s clefts two transmembrane protein
- REX: Ring exported proteins
- RIFIN: Repetitive interspersed family proteins
- STEVOR: Subtelomeric variable open reading frame proteins
- SURFIN: Surface-associated interspersed gene family proteins
- VSA: Variant surface antigen

Introduction

*Plasmodium falciparum* is the most virulent form of human malaria and is a leading cause of mortality among children under 5 years [1]. *Plasmodium falciparum* has a complex
lifecycle involving a mosquito vector and a human host. The on-going asexual reproduction during the blood stage leads to clinical symptoms of malaria [2]. The pathogenesis of human malaria stems from various host and parasite factors that concurrently influence the severity and outcome of disease. Key pathophysiological features include the sequestration of *P. falciparum*-infected erythrocytes (IEs) in the microvasculature, the induction of proinflammatory cytokines and anemia resulting from the suppression of erythropoiesis [2, 3]. The destruction of uninfected erythrocytes and IEs further compromises oxygen delivery and exacerbates disease pathogenesis [4]. An important virulence property of *P. falciparum* is the expression of parasite-derived antigens on the surface of IEs, generally known as variant surface antigens (VSAs; Fig. 1), and its strong propensity to adhere in the vasculature. VSAs are comprised of novel parasite-derived proteins and include *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) [5], repetitive interspersed family (RIFIN) proteins [6–8], sub-telomeric variable open reading frame (STEVOR) proteins [9–11], surface-associated interspersed gene family (SURFIN) proteins [12] and possibly others such as *P. falciparum* Maurer’s cleft two transmembrane (PfMC-2TM) proteins [13, 14]. Parasite-modified erythrocyte band 3 has also been proposed as a surface antigen or ligand for IE sequestration [15, 16]. These IE surface proteins are antigenically diverse and undergo clonal antigenic variation because of the selective pressure exerted by human immunity. The significance of VSAs as targets of naturally acquired immunity and their potential as vaccine candidates is the focus of this review. Acquired immunity to blood stage *P. falciparum* will be addressed, followed by a summary of the VSAs expressed on the IE surface and finally human antibodies to different VSA families.

**Plasmodium falciparum** sequestration and cytoadhesion

The virulence of *P. falciparum* malaria is attributed to the adhesion of IEs to the vascular endothelium or to uninfected erythrocytes to form rosettes [17–19]. Mature *P. falciparum* disappear from the peripheral circulation and are sequestered in various organs throughout the body. The importance of splenic clearance of IEs in controlling disease severity has been demonstrated by numerous studies. For example, a study conducted with *Aotus* monkeys showed that splenectomised animals developed virulent infections, presumably because of enhanced accumulation of IEs in the microvasculature [20, 21]. IE sequestration contributes to the pathogenesis of severe disease syndromes such as cerebral [17, 22, 23] and placental complications [24, 25]. An important feature of IEs that enables *P. falciparum* to sequester is the expression of knob structures on the IE membrane [26–28]. The major structural component of knobs is the knob-associated histidine-rich protein (KAHRP) [27, 29–32]. Other parasite-encoded proteins such as *P. falciparum* erythrocyte membrane protein 3 (PfEMP3) [33] and mature IE surface antigen (MESA; also known as PfEMP2) [34, 35] also contribute to knob assembly. KAHRP interacts with cytoskeletal components of the erythrocyte such as spectrin and actin [36–38], resulting in reduced membrane deformability [39]. Knobs present the major virulence factor, PfEMP1 [5], on the external surface of the IE membrane, where it mediates
IE cytoadhesion to the host endothelium under physiological flow conditions [40, 41]. Disruption of the kahrp gene impairs proper knob formation and leads to a decrease in surface-exposed PfEMP1 and reduced cytoadhesion [42]. However, the presence of knobs may not necessarily result in sequestration [43]; P. malariae has knobs structures but does not sequester, while P. chabaudi sequesters without knobs [16, 43].

A diverse range of host receptors that mediate IE cytoadhesion has been identified [44–46]. The main parasite ligand responsible for cytoadhesion is PfEMP1 and it binds to a range of endothelial and erythrocyte molecules including CD36 [47], ICAM-1 [48], chondroitin sulphate A (CSA) [49, 50], complement receptor 1 (CR1) [51], heparan sulfate (HS) [52] and others. IEs are capable of binding via multiple receptors [53] therefore creating a synergistic effect on IE adhesion [54]. Most P. falciparum isolates adhere to both ICAM-1 and CD36, which are widely distributed in the vasculature [53, 55, 56], but parasites isolated from infected placentas mainly adhere to specific receptors expressed by the syncytiotrophoblasts of the infected placenta [57, 58], particularly CSA [56, 59, 60], and possibly secondary receptors such as hyaluronic acid (HA) [61–63] and non-immune IgM [64–66] and IgG [67]. The differential expression of endothelial cell receptors in various tissues leads to the preferential binding of IEs. For example, it is proposed that ICAM-1-binding parasites are more likely to sequester in the brain [46, 68] as the brain endothelium expresses ICAM-1. While it has been speculated that receptor-specific adhesion (e.g. ICAM-1) predisposes to a particular pattern of disease (e.g. cerebral malaria), studies to date have been inconclusive. In one study, cerebral malaria patients did not show a significant association between disease and ICAM-1 binding [69], and another study reported that ICAM-1-binding was lowest in children with severe malaria [70]. In contrast, post-mortem histopathological analyses of infected cerebral vessels proposed a role for ICAM-1 in the manifestation of severe disease [68], and another study demonstrated that ICAM-1-binding was greater in cerebral malaria patients compared to patients with uncomplicated malaria [71]. This may propose a role for ICAM-1 in the pathogenesis of cerebral malaria but additional studies are necessary to further validate this association. A recent study identified endothelial protein receptor C as a likely mediator of cerebral sequestration [72]. Other host receptors implicated in IE cytoadherence include thrombospondin (TSP) [73], platelet/endothelial cell adhesion molecule (PECAM/CD31) [74], P-selectin [75] and vascular cell adhesion molecule-1 (VCAM-1) [53], but the significance of these receptors in disease pathogenesis remains unclear.

The clustering of mature IEs to uninfected erythrocytes, known as rosetting [76], is also thought to contribute to excessive microvasculature obstruction [77, 78]. Rosetting is associated with severe malaria in African children, suggesting that it contributes to disease pathogenesis [79–83]. However, a study with Malawian [70] and PNG [84] children reported that the rosetting occurred at a similar rate between children with severe and uncomplicated malaria, suggesting that rosette formation is not always associated with severe clinical outcomes. The parasite ligand for rosetting in P. falciparum has been identified as a specific PfEMP1 variant that binds to CR1 [51] or HS proteoglycans [85] expressed by the host erythrocyte.

Plasmodium falciparum also causes vascular obstruction through the clumping of IEs, a feature that was first reported as autoagglutination [86]. This adhesive phenotype is distinct from rosetting, as autoagglutinating parasites do not form rosettes and rosetting parasites do not autoagglutinate [86]. Autoagglutination was a common feature of infection, although more autoagglutinates were observed in children with severe malaria compared to those with mild malaria. This suggests that autoagglutination is more frequently observed in, but not restricted to, severe disease [87]. It was later reported that autoagglutination is mediated by platelets and required the expression of the platelet glycoprotein CD36 [88]. Scanning electron microscopy of platelet-mediated clumping of IEs showed that this interaction occurred at the IE knob structures [88]. Studies with Kenyan children [88] and patients from Thailand [89] established that platelet-mediated clumping of IEs was associated with severe disease, presumably through local disruptions of blood flow. Conversely, binding of platelets to IEs has also been implicated in protection against P. falciparum by directly inhibiting intra-erythrocytic parasite growth [90, 91].

VSAs of P. falciparum

The most extensively studied VSA is the major virulence factor PfEMP1, an important target of naturally acquired immunity [92, 93]. The var genes that encode PfEMP1 appear to be unique to P. falciparum, but the P. knowlesi schizont-infected cell agglutination (SICA) antigens encoded by the SICAvar multigene family [94, 95] have been described as conceptually similar to PfEMP1 [96]. Orthologs of rif and stevor genes have been identified in other Plasmodium species, known collectively as the pir multigene family (Plasmodium interspersed repeats). These include the pir multigene family in P. vivax [97], kir multigene family in P. knowlesi, yir multigene family in P. yoelii, bir multigene family in P. berghei and cir multigene family in P. chabaudi [98, 99].

Currently, little is known regarding the mechanisms that regulate gene transcription in P. falciparum other than...
the involvement of specific transcription factors and promoter interactions. Exploiting the mutually exclusive transcription of var genes has allowed for the suppression of the entire endogenous var multigene family [100, 101], thus enabling the specific study of PfEMP1 [102]. Conversely, disrupting up to 150 genes such as in the rif family is not currently feasible, and knockdowns of rif, stevor and pfmc2tm gene families have not been achieved. These multigene families share a common activation factor necessary for gene expression, and it has been proposed that the downregulation of one multigene family may affect the expression of members of other multigene families in some conditions [103]. A transcriptionally active rif promoter co-localised with an active var promoter and the downregulation of members in the stevor multigene family appeared to increase transcription of the pfmc-2tm multigene family [103]. Further studies must be employed to dissect the functional roles of these multigene families.

It is hypothesised that a large proportion of parasite proteins exported into the host erythrocyte supports the correct trafficking and surface display of PfEMP1 and other erythrocyte surface proteins. This also includes alterations in the spectrin network and knob protrusions at IE membrane [104]. Many exported proteins contain a pentameric sequence, known as the Plasmodium export element (PEXEL) [105] or vacuum translocation signal [106], required for the translocation of proteins across the PV membrane. Exported parasite proteins such as PfEMP1 are trafficked via the translocon complex (PTEX; Plasmodium translocon of exported proteins) located at the parasitophorous vacuole (PV) [107, reviewed in 108]. Most parasite proteins are destined for the IE cytosol, and only a small portion is exposed on the IE surface. Interestingly, recent studies have shown that exported parasite proteins may play a role in cellular communication between IEs through microvesicles [109] and exosome-like vesicles [110]. Microvesicles lack components of the knob structure like KAHRP and PfEMP1, suggesting that they originate from MC structures or regions of the erythrocyte membrane that exclude knobs [109]. It was further demonstrated that PfEMP1 is not required for efficient intercellular communication as modified parasites with inhibited PfEMP1 expression were still able to receive exosome-like vesicles [110].

PfEMP1 and var genes

PfEMP1 was first identified by immunoprecipitation with immune sera from infected Aotus monkeys [5] and is encoded by the highly polymorphic var multigene family (~60 genes per genome) [40, 111, 112]. Through mutually exclusive transcription of var genes, only a single PfEMP1 variant is generally expressed on the IE surface at a given time [52, 113]. However, a recent study reported the potential expression of more than one PfEMP1 variant on the IE surface as demonstrated by live confocal microscopy, in vitro adhesion assays and cell sorting by flow cytometry [114]. PfEMP1 is a high-molecular-weight protein (200–350 kDa) and is highly sensitive to cleavage by mild trypsin treatment of intact IEs (10 μg/ml) [5]. The biochemical properties of PfEMP1 (Triton X-100-insoluble and SDS-soluble) demonstrate its anchorage to the IE membrane [115].

The export of PfEMP1 is a highly complex process due to its large size, number of membranes to traverse before reaching the IE surface and the involvement of various chaperone proteins (reviewed in [116, 117]). PfEMP1 molecules are associated with the Maurer’s clefts (MCs) and are ultimately presented by the knob structures at the IE surface at approximately 18 h post-invasion [5, 32, 115, 118–120]. The mechanism of transport of PfEMP1 from the parasite to the IE surface as well as its partner proteins involved remains a process that is poorly defined.

An important MC-resident protein essential for PfEMP1 trafficking is the 48 kDa P. falciparum skeleton binding protein 1 (SBP1) [121–123]. Disruption of the pfsbp1 gene impaired the loading of PfEMP1 molecules into the MCs and resulted in the loss of surface-exposed PfEMP1, but the trafficking of other MC proteins such as KAHRP, MAHRP1 and REX1 was unaffected in the transgenic parasites [122, 123]. A large-scale gene knockout screen further identified MC proteins termed P. falciparum PfEMP1 trafficking protein (PfPTP) involved in the trafficking of PfEMP1 to the IE surface [124]. Of the 83 P. falciparum genes that were disrupted, 6 genes were specifically found to affect the export and surface display of PfEMP1, and 2 were found to disrupt proper knob formation. In these transgenic parasites, PfEMP1 export was arrested either at the PV or the MC structures in the IE cytosol [124]. Among the proteins involved in the trafficking of PfEMP1 are members of the HSP40/DNAJ and PHIST family [124]. Recently, an exported parasite-encoded HSP70 known as PHSP70-x was found to complex with HSP40s and co-localised with PfEMP1 in the IE cytosol [125]. Other MC-associated proteins that have been proposed to play a role in the trafficking of PfEMP1 include MAHRP [126], REX1 [127] and Pf332 [128].

Transcription of var genes is epigenetically regulated by the SIR complex as gene disruption of PSir2 results in activation of multiple members of this multigene family [129–131]. The rapid switching rate of var genes, of up to 2 % per generation [86], was demonstrated to correlate with changes in IE adhesive and antigenic phenotypes [112, 132]. The typical structure of PfEMP1 includes the variable N-terminal segment (NTS) exposed on the IE surface to interact with host receptors [133], a transmembrane
Surface antigens of *Plasmodium falciparum*-infected erythrocytes

3637

domain and a conserved acidic terminal segment (ATS) [48]. The cytoplasmic ATS domain interacts with KAHRP [134–136], thus anchoring PfeMP1 to the IE membrane. The extracellular portion of PfeMP1 consists of Duffy binding-like (DBL) adhesive domains, the C2 domain and the cysteine-rich interdomain regions (CIDR) [48]. DBL domains are grouped as five sequence classes (α, β, γ, δ, ε), and CIDR domains are grouped as three distinct classes (α, β, γ). While the number of CIDR and DBL domains may vary between different PfeMP1 variants, certain domain architectures such as DBLα-CIDRα or DBLδ-CIDRδ are preferred. This conservation may reflect the biological function of PfeMP1 [48]. The binding site of ICAM-1 resides within the DBL2β and c2 regions of PfeMP1 [137, 138], while the binding site of CD36 is mapped to the CIDRα region [47, 139, 140]. The binding site of CSA in pregnancy-associated parasites lies within the DBL1-DBL3 domain of PfeMP1 [141].

The var genes can be classified into three main subgroups based on their upstream promoter regions (upsA, upsB and upsC) and the single-copy conserved intergenic genes var1 and var2csa [142–145]. The var gene repertoires of clinical isolates can also be classified according to short sequence tags amplified from the DBLα domain [146, 147]. Analyses of the DBLα sequences from Kenya showed the presence of two or four cysteine residues, with a minority containing one, three, five or six cysteines; therefore, var genes were sub-grouped according to cys2, cys4 and cysX, respectively [147]. These DBLα sequences were further classified according to the amino acid motifs occurring at four fixed positions within the sequenced region, known as “positions of limited variations” (PoLV1-4) [147]. Expression of var genes from the cys2 group was associated with severe malaria in young children [148, 149]. The differential transcription of var gene subgroups has been linked to clinical disease. Transcription of group A var genes was also associated with rosetting parasites [150] and severe malaria in African children [151–153]. Furthermore, the elevated expression of group A-like var genes was associated with impaired consciousness, a key feature of severe disease [154]. Recent studies also reported the expression of a restricted subset of var genes encoding PfeMP1 variants that bind human brain endothelial cells [155, 156]. These var genes belong to group B/A genes that are expressed in early childhood infections [148, 157] and are associated with more severe infections [149, 151]. PfeMP1 variants from group B and C var genes are also associated with autoagglutination and ICAM-1-binding, features that contribute to severe disease [133, 138]. The lack of association between transcription of var group C and clinical presentation suggests that perhaps these var genes are involved in the establishment of chronic infections [158]. These findings support the correlation between var gene expression patterns and clinical presentations, thus suggesting that protective immunity could be conferred by antibodies to key var gene subgroups [147, 158].

A specific var gene, var2csa, is relatively conserved in sequence and is present as a single-copy gene in most isolates. However, some isolates have more than one copy of var2csa (e.g. HB3 has two copies of var2csa) [159–161]. This gene is upregulated in placental isolates and mediates IE adhesion to CSA and other placental receptors such as HA and immunoglobulins [162–165]. Polyclonal antibodies generated against recombinant domains of VAR2CSA recognised the IE surface of parasites isolated from infected placental tissue [166]. Furthermore, sera from pregnant women recognised the IE surface of VAR2CSA-expressing parasites in a parity-dependent manner [164, 167]. Pregnant women with elevated levels of these antibodies had a reduced risk of delivering low-birth-weight babies [164]. Targeted gene disruption of var2csa in the isolates FCR3 [168] and 3D7 [169] inhibited CSA adhesion, suggesting the central role of var2csa in mediating placental adhesion. In contrast, disruption of var2csa in CS2 parasites also ablated CSA binding but repeated selection on CSA restored their binding ability [169] presumably through the expression of other PfeMP1 variants proposed to bind CSA [49]. The use of different parasite lines may reflect the discrepancies between these studies and that the FCR3 or 3D7 isolates lack the PfeMP1 variants thought to rescue the CSA-binding ability.

The var transcripts have also been detected by RT-PCR in both immature (I–II) and mature stage gametocyte-IEs (IIB–V). Initial studies suggested that the var genes transcribed in gametocyte-IEs were similar or identical to those expressed by asexual parasites [170]. However, it was later discovered that the var transcript profile was unlinked to their asexual progenitors. Furthermore, it appears that the most abundant var transcripts found in gametocyte-IEs (generated in vitro) belong to the non-subtelomeric group C var genes [171]. Data regarding the pattern of PfeMP1 expression in gametocyte-IEs are conflicting. Early studies reported the expression of PfeMP1 in all five stages of gametocyte development but with stage-specific patterns. PfeMP1 staining was visualised at the IE membrane of immature gametocyte-IEs (stages I–IIA) but not of mature gametocyte-IEs (IIB–V) [170]. A recent study reported low levels of PfeMP1 expression on the surface of immature gametocyte-IEs, which was absent in mature gametocyte-IEs [172]. Thus, it is thought that sequestration of immature gametocyte-IEs is mediated by PfeMP1, after which its role is replaced by an alternative ligand present on the surface of mature gametocyte-IEs or through mechanical effects [173].
RIFIN proteins

The rif multigene family (150–200 genes per genome) encoding a group of clonally variant RIFIN proteins represents the largest multigene family identified in *P. falciparum* [6–8]. Transcription of rif genes occurs approximately 12 h post-invasion, but RIFIN proteins are thought to appear on the IE surface at the same time as PfEMP1 [174]. In contrast to var genes, a single parasite simultaneously transcribes several rif genes, resulting in the expression of multiple RIFIN variants on the IE surface [8]. All RIFIN sequences contain the PEXEL motif required for correct export [105]. Surface exposure of RIFIN was evident from immunoprecipitation and Western blot analyses. Bands of expected size corresponding to RIFIN (30–45 kDa) were absent after IEs were treated with high concentrations of trypsin (>100 µg/ml), a concentration much greater than that needed to cleave the highly trypsin-sensitive PfEMP1 [7, 8]. Some variants of the large RIFIN family are also expressed in other developmental stages such as merozoites, sporozoites and gametocytes [175–177]. Bioinformatic analyses of RIFIN sequences revealed two major subgroups of the RIFIN family [178] that are simultaneously expressed in a single parasite. A-type RIFINs associate with the MCs and are destined for the IE surface, whereas B-type RIFINs remain confined within the parasite [176]. Although the biological function of RIFIN remains unknown, the exposure of their highly polymorphic v2 epitope on the IE surface suggests they contribute to antigenic variation of *P. falciparum* [6, 179]. Although direct evidence is lacking, RIFIN was proposed to play a role in rosetting [7, 8].

STEVOR proteins

The stevor multigene family, encoding STEVOR proteins (~30–40 kDa), is the third largest identified in *P. falciparum* (reviewed in [10]). First described as 7h8, stevor was detected by a monoclonal antibody as an expressed sequence [6]. Each parasite genome is predicted to contain approximately 30–40 copies of stevor genes. Like var and rif, stevor genes are located at the telomeres of most *P. falciparum* chromosomes [6]. Similar to rif, multiple stevor transcripts were detected in a single parasite. Peak stevor transcription occurs at 28 h post-invasion during late trophozoites and early schizonts, where they appear to localise in the IE cytosol. As the parasite matures, STEVOR co-localises with PfSBP1 and PfEMP3 at the MCs [9, 180] in immunofluorescence microscopy with fixed IEs [10, 11]. Immunofluorescence microscopy with live, intact schizont stage IEs suggests the surface localisation of STEVOR, which was removed upon IE trypsinisation [11, 181]. A recent study demonstrated that stevor overexpression contributes to increased IE rigidity [182], together with other IE cytoskeletal members such as RESA [183]. It is proposed that STEVOR-increased stiffness of IEs enhances PfEMP1-mediated IE sequestration [182]. The biological function of STEVOR remains unclear. Because STEVOR is clonally variant [13, 184], it may be involved in immune evasion concurrently with PfEMP1 and RIFIN [10, 11, 13]. In addition, STEVOR has been proposed to play a role in parasite invasion [185]. STEVOR proteins are also expressed in merozoites [10, 186, 187], sporozoites [175] and gametocytes [9]. Interestingly, the same STEVOR variants are transcribed in gametocytes and their asexual progenitors, suggesting that perhaps STEVOR plays a similar role in these lifecycle stages [171].

SURFIN proteins

Little is known about the surf multigene family (10 genes), which encodes high-molecular-weight antigens (~280–300 kDa) known as SURFIN proteins [12]. The expression of surf genes is differentially transcribed according to different stages of the intra-erythrocytic parasite. The expression of surf13, surf4.2 and surf6.3 genes was detected throughout parasite development while other surf genes were either not detected or restricted to later developmental stages [188]. A variant expressed by 3D7 and FCR3 parasites, SURFIN4.2, was identified by mass spectrometric analysis of proteins cleaved off the surface of intact IEs by trypsin [12]. SURFIN4.2 was only detected in a subpopulation of cultured IEs (~25 %) with increasing protein expression during mature developmental stages (24–44 h post-invasion). Immunoelectron microscopy showed the presence of SURFIN4.2 at the knob structures suggesting its co-localisation with PfEMP1 at the IE surface [12]. However, attempts to verify the surface localisation of SURFIN4.2 proteins with live, intact IEs were inconclusive. Another variant, SURFIN4.1, localised to the parasitophorous vacuole (PV) but not within the erythrocyte cytosol in mature IEs (>30 h post-invasion) [188]. SURFIN antibodies did not agglutinate mature IEs and no fluorescence was observed with live IEs, suggesting that SURFIN4.1 is not exposed on the IE surface [188]. Whether SURFIN proteins potentially elicit humoral immunity or mediate immune evasion has not been determined.

Other membrane proteins

*Plasmodium falciparum* Maurer’s clefts two-transmembrane protein (PfMC-2TM) is encoded by a novel gene family (~13 members) located at the subtelomeric regions of several *P. falciparum* chromosomes [14, 142]. PfMC-2TM is highly conserved within the N-terminus, both
transmembrane domains and the C-terminus. The short loop between the transmembrane domains is highly polymorphic, similar to that proposed for RIFIN and STEVOR [13, 184]. The diversity within this loop region proposed the inclusion of pfmc-2tm as a variant multigene family together with var, rif and stevor [13, 14]. It has not been determined whether PfMC-2TM is associated with the IE membrane or exposed on the IE surface.

Another IE membrane protein is modified erythrocyte band 3, which has been proposed as a ligand for IE adhesion to CD36 [189] and thrombospondin [190, 191]. Chemical modifications of band 3 led to a reduction in CD36 binding but not thrombospondin, thus supporting its role in CD36 adhesion [189]. Synthetic peptides based on the exofacial loops of band 3 and antibodies generated against these peptides were capable of inhibiting IE adhesion to C32 amelanotic melanoma cells. Additionally, intravenous infusion of these peptides into Aotus and Saimiri monkeys infected with P. falciparum isolates prevented IE sequestration [192]. However, its significance in relation to PfEMP1 as an adhesive ligand remains unclear. In our recent study, parasites with suppressed PfEMP1 expression were found to retain a substantial proportion of CD36 binding, but not ICAM-1, thus raising the possibility that additional surface antigens contribute to CD36 adhesion [102].

Naturally acquired immunity to malaria

Protective immunity to malaria is elicited through complex interactions between both humoral and cell-mediated responses [193–195]. This protection against symptomatic malaria in humans develops gradually after repeated exposure to P. falciparum infections (reviewed in [196]). In malaria-endemic areas, the risk of severe disease is greatest during the first few years of life, after which the risk rapidly declines as children begin to acquire natural immunity. A study of young African children reported that immunity to non-cerebral severe malaria may develop after several infections and is almost complete by the age of 5 [197]. Adolescents and adults eventually develop protection from severe illness and death, although sterile immunity is rarely or perhaps never achieved [198]. Maternal antibodies transferred across the placenta are also thought to confer protection in young infants [199, 200]. It is becoming increasingly clear that effective immunity to malaria involves immune responses to multiple antigens expressed at different parasite stages and requires multiple immune effector mechanisms [195]. It is likely that the development of a highly effective malaria vaccine will require the inclusion of multiple antigens and that single-antigen vaccines will not be optimally efficacious.

Cell-mediated immunity to VSAs

While the significance of humoral immunity to P. falciparum is well established in humans, the role of cell-mediated immunity (CMI) remains poorly understood. CMI acts through complex interactions with the innate and adaptive immune response (reviewed in [195, 201]). Most studies of CMI have been based on murine models of malaria (reviewed in [202]). Early studies showed that mice incapable of making B cells have the ability to control infection [203], suggesting the importance of CMI in protection against malaria. Antigen-presenting cells process parasite antigens for display on major histocompatibility complex molecules to recruit antigen-specific CD4+ T cells. Th1 cells produce proinflammatory cytokines such as TNF-α and IFN-γ, which lead to monocyte activation and the release of toxic mediators that limit P. falciparum growth [204]. In a study of Gabonese children, IFN-γ responses to erythrocytic antigens were associated with lower rates of P. falciparum reinfection [205]. Despite this protective potential, CMI responses have also been implicated in disease pathogenesis and the development of severe malaria (reviewed in [206]).

Although data on CMI responses to VSAs are limited, studies have reported that parasites may modulate CMI to evade host immune responses. For example, the maturation of dendritic cells cultured in vitro was suppressed following exposure to erythrocytes infected with P. falciparum [207]. It was later reported that the modulation of dendritic cells was not dependent on the interaction between PfEMP1 and CD36 [208]. Interaction between IEs and natural killer (NK) cells leads to their activation, including production of IFN-γ [209]. A recent study using a humanised mouse model has reported that NK cell binding of IEs leads to the activation of NK cells and the elimination of IEs [210]. Using parasites with modified PfEMP1 expression, others reported that PfEMP1 appeared to suppress innate IFN-γ production by naive CD4+ T cells and NK cells [211]. The CIDR1α domain of PfEMP1 was found to induce polyclonal B cell activation that contributes to the evasion of host immune responses [212–214] and stimulates CD4+ T cells from both malaria-exposed and non-exposed individuals [215]. The addition of recombinant CIDR1α to naïve human peripheral blood mononuclear cells resulted in the activation of CD4+ T cells and NK cells, leading to IFN-γ production [216]. It appears that a fine balance between protective immunity and immunopathology must be achieved in CMI. The lack of CMI-related studies in human malaria and the difficulty of inferring results from murine models are continuing obstacles in our understanding of the role of CMI and a priority topic for further research.
Human antibodies to VSAs

The development of protective immunity to \textit{P. falciparum} is characterised by a decrease in disease severity over several years after repeated infections [217]. Sterile immunity to \textit{P. falciparum} is rarely achieved, as adults living in malaria-endemic regions remain susceptible to asymptomatic infection and often experience persistent low levels of parasitaemia without clinical disease [196, 198]. The passive transfer of gamma-globulin from immune individuals to \textit{P. falciparum}-infected individuals confers protection against malaria infection [218]. Antibodies to both merozoite antigens [219–221] and VSAs appear to play an important role in mediating acquired immunity. The focus of this review is on VSAs, and the significance of merozoite antigens as immune targets is reviewed in detail elsewhere [222]. In brief, numerous antigens on the surface of merozoites (e.g. merozoite surface protein 1, 2, and 3) and erythrocyte invasion ligands (e.g. erythrocyte-binding antigens, PfRh invasion ligands and apical membrane antigen 1) have been identified as important targets of acquired immunity and promising vaccine candidates [219–221, 223, 224]. Although it is highly likely that antibodies to VSA and merozoite antigens contribute to immunity and a strong response to both types of antigens may be essential for highly effective immunity, there are few reports on the relationship between these responses and how they may interact to mediate immunity [225]; this is an important question for further research.

Naturally acquired antibodies against VSAs typically demonstrate a high degree of strain specificity [132, 226]. Antigenic diversity by \textit{P. falciparum} enables repeated infections to occur over time, as new infections appear to exploit gaps in the repertoire of previously acquired variant-specific antibodies [226]. Antibodies to polymorphic VSAs expressed on the IE surface, such as PfEMP1, have been proposed to play a key role in mediating protective immunity [93, 226–228]. Most published studies used agglutination assays to describe antigenic variation in PfEMP1 as switches in \textit{var} gene expression [112] or PfEMP1 [132]. However, it is difficult to determine PfEMP1-specific antibody responses because of the number of antigens expressed on the IE surface; therefore, antibodies measured to the IE surface are hereafter classified as antibodies to all VSAs (studies summarised in Table S1).

Early studies that measured agglutination antibody responses to \textit{P. falciparum} infections in Pakistan [229], Papua New Guinea [230] and Africa [226, 231] reported that children developed isolate-specific antibodies to VSAs after infection. Mixed agglutination assays that allowed the determination of shared epitopes on the IE surface also showed that acquired human antibodies are predominantly variant specific while cross-reactive antibodies are rare [231]. However, antibodies from convalescent sera from adults were capable of agglutinating diverse \textit{P. falciparum} isolates [232], and antibodies acquired towards placental-binding parasites expressing VAR2CSA have a significant amount of cross-reactivity against different isolates, despite polymorphisms in VAR2CSA [159, 233]. Furthermore, an acute \textit{P. falciparum} infection in returned travellers was sufficient to induce broadly cross-reactive antibodies that were relatively long lived (>20 weeks post-infection) [208], thus suggesting that cross-reactive antibodies are prevalent following infection. The molecular basis for this remains unclear but may be due to extensive sharing of polymorphic epitopes between PfEMP1 variants [159, 234]. In an early study, parasite isolates from ten Gambian children were tested in a checkerboard manner with the acute and convalescent sera collected from each child [226]. Most of the acute sera were not reactive towards the parasite isolate from that same child, whereas each of the serum samples collected during convalescence were highly reactive to the IE surface of the isolate from the same child but not from other children [226]. This study suggested that the VSAs expressed on the IE surface are highly diverse and children tend to acquire antibodies towards the variants expressed by the parasite causing that particular episode. Moreover, hyperimmune sera from Gambian adults agglutinated IEs from those ten children, suggesting that by adulthood most individuals have acquired a broad range of antibodies that protect against numerous parasite variants [226], and the presence of cross-reactive antibodies was also proposed. A large prospective study of young Kenyan children further showed that parasite variants expressed during episodes of clinical infection were less likely to be recognised by homologous sera collected before infection. This suggests that the variants are exploiting gaps in the pre-existing antibody repertoire in order to cause subsequent infections [227]. Consistent with that observation, antibodies from Sudanese children measured after the malaria season could agglutinate a broader range of isolates tested compared with antibodies measured before the season [235]. This suggests that natural \textit{P. falciparum} infections are capable of inducing high antibody titres directed towards VSAs of the infecting parasite. In a cross-sectional study of Kenyan children during the low transmission season, antibodies to VSAs were higher in parasitaemic individuals, suggesting that these antibodies were induced by current infections [236]. Furthermore, plasma antibody levels were positively correlated with age, indicating an age-related and exposure-related component in the acquisition of VSA-specific antibodies [237].

The importance of antibodies to VSAs is evident through their role in mediating protective immunity to malaria (studies are summarised in Table 1). For example,
in a longitudinal study conducted with young Gambian children, acquired antibodies to VSAs from several different isolates were consistently associated with protection from clinical malaria [228]. In Gabonese children, higher levels of IgG to VSAs were associated with lower rates of malaria [238]. A study of Ghanian children demonstrated that those with pre-existing antibodies before the malaria season were less likely to contract malaria than those with low levels of antibodies [239]. Furthermore, the presence of antibodies to a Ghanian isolate was significantly associated with protection from malaria [240]. However, the ability of sera from Kenyan children to recognise VSAs expressed by a Kenyan isolate was not associated with protection from malaria [227]. It appears that anti-VSA antibodies to some but not all parasite isolates are associated with protection [236, 239, 240], and presumably this depends on the prevalence of the parasite variant and its virulence properties. Nonetheless, evidence from all of the studies presented above supports the important contribution of anti-VSA antibodies to protection against malaria.

Despite the apparent role of PfeMP1 antibodies in mediating protection against malaria, the immense diversity of PfeMP1 limits its potential as a vaccine candidate. Although the repertoire of PfeMP1 variants is large, studies have suggested the expression of a dominant subset of variants that are restricted by their biological function in clinical disease. Immune sera from distinct geographic regions agglutinated IEs from other populations, suggesting that antibodies targeted cross-reactive epitopes expressed by many isolates [241]. Another study demonstrated that plasma antibodies were capable of recognising various parasite isolates regardless of the geographic origin of those IEs, suggesting that the repertoire of VSA-specific antibodies may be conserved over different populations [242]. A study in Kenya demonstrated that parasites isolated from children presenting with severe malaria were recognised by heterologous plasma antibodies, suggesting the expression of common PfeMP1 variants in this population [92]. Similarly, IEs from young Ghanian children with severe malaria were more commonly recognised by plasma antibodies from other children than those with uncomplicated malaria [243]. This suggests that a restricted subset of variants is expressed during severe disease to which antibodies are rapidly acquired [197]. These studies propose that the infecting parasites causing severe disease may be expressing a commonly expressed subset of VSA variants [236, 237]. A limitation of these studies is that they were only able to measure antibodies directed towards all VSAs expressed on the IE surface and not the proportion of antibodies to individual VSAs such as PfeMP1.

Little is known about antibody responses directed at antigens expressed on the surface of erythrocytes infected with gametocytes during their development in the human host. Such antigens could potentially elicit immune responses, similar to those of asexual parasites, which may result in the clearance of gametocytes in the host. Sera from Gambian children were reported to be highly reactive towards the surface of mature stage gametocyte-IEs but not towards immature stage gametocyte-IEs [244]. This may suggest that the antigens recognised by the serum antibodies in mature gametocyte-IEs are distinct from those expressed by immature gametocyte-IEs [244]. However, another study showed that sera from children in Papua New Guinea (PNG) were highly reactive to the surface of immature gametocyte-IE, similar to that observed with asexual trophozoite IEs, but not towards the surface of mature gametocyte-IEs [245]. These conflicting results demonstrate that further work is needed to better understand the antibody response directed towards antigens on the surface of gametocyte-IEs. Antibodies targeting these surface antigens represent potential vaccine candidates as they may mediate gametocyte clearance from the circulation, thus leading to reduced malaria transmission. More importantly, understanding the humoral response elicited by antibodies on the surface of gametocyte-IEs will shed light on how these antibodies potentially act in synchrony with antibodies to other parasite stages to clear parasitaemia and reduce transmission.

Human antibodies to PfeMP1

Epidemiological data have demonstrated that naturally acquired antibodies predominantly target variant-specific epitopes on the IE surface and PfeMP1 is thought to be a major antibody target. Lacking the molecular tools required to evaluate the significance of PfeMP1 independently of other VSAs, most studies have relied on the use of recombinant purified PfeMP1 domains to study human antibody responses to PfeMP1 (studies summarised in Table S2). A recent study in PNG used a DBLα protein microarray to demonstrate that the magnitude of the anti-PfeMP1 response was limited and variant specific in young children (<3 years of age), after which a broader spectrum of antibody recognition was achieved. By adulthood, serum antibodies were capable of recognising at least 20 different variants indicating an expansion of the PfeMP1 antibody repertoire [246]. Consistent with the preferential expression of PfeMP1 variants in severe disease [151, 152], the acquisition of anti-PfeMP1 antibodies by Tanzanian children was reported to be highly structured. Antibodies to different recombinant PfeMP1 domains were sequentially acquired, with children first acquiring antibodies to particular variants encoded by group A var genes [157, 247]. These findings were supported by another study whereby PfeMP1 DBLα domains were linked to young host age, disease severity and low levels of immunity [148].
Table 1  Studies examining the association between human antibodies to vSAs and protection against malaria

| Province, Country       | Study                      | Population (n) | Age             | Parasite isolates                      | Findings<sup>a</sup>                                                                 |
|-------------------------|----------------------------|----------------|-----------------|----------------------------------------|---------------------------------------------------------------------------------------|
| Farafenni, The Gambia   | Marsh et al. [228]          | Children (134) | <11 years       | Gambian isolate (GAM83/1)              | Antibodies to the IE surface were prospectively associated with protection against clinical episodes of malaria |
| Lambaréne, Gabon        | Tebo et al. [238]           | Children (200) | 6 months–11 years | IEs from 3 donor children              | Convalescent sera from children with mild malaria had higher anti-VSA IgG compared to matched children with severe malaria |
| Dodowa, Ghana           | Dodoo et al. [239]          | Children (118) | 3–15 years      | IEs isolated from children             | IgG to VSA correlated with protection from clinical malaria                             |
| Daraweesh, Sudan        | Giha et al. [240]           | Adults and children (39) | 5–50 years     | IEs isolated from children             | Antibodies to Ghanian isolate were significantly associated with protection            |
| Kilifi, Kenya           | Bull et al. [227]           | Children (65)  | 1–5 years       | Kilifi isolate (1759)                  | Lack of association between antibodies to the Kilifi isolate and protection from malaria |
| Kilifi, Kenya           | Bull et al. [236]           | Children (84)  | 1–5 years       | IEs isolated from children             | No association between anti-VSA antibodies or parasite positivity and protection from malaria |
| Lambaréne, Gabon        | Yone et al. [288]           | Children (100) | 1–8 years       | IEs isolated from 6 donor children     | Convalescent-phase IgG1 was associated with clinical protection                          |
| Kilifi, Kenya           | Mackintosh et al. [289]     | Children (272) | 6 months–10 years | Reference parasites (A4, 3D7), 1 clinical isolate from a Kenyan child | Failure to mount antibodies against these isolates was associated with malaria susceptibility in children with asymptomatic parasitaemia |
| Kilifi, Kenya           | Chan et al. [102]           | Children (296) | 1–10 years      | Reference parasites (3D7, E8B) and genetically-modified parasites | PIPMP1 is a dominant target of antibodies and PIPMP1-specific antibodies were associated with protection against symptomatic malaria |

PubMed was searched for studies that examined the association between acquired human antibodies to total vSAs and protection against malaria, without an exclusion criterion, and attempts were made to include most studies.

<sup>a</sup> Not all findings are listed for all studies.
Table 2  Studies examining the association between human antibodies to PfEMP1 and protection against malaria

| Province, country | Study                   | Population (n) | Age          | Antigen\(^a\)                              | Findings\(^b\)                                                                                                                                                                                                 |
|------------------|-------------------------|----------------|--------------|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dodowa, Ghana    | Dodoo et al. [239]      | Children (118) | 3–15 years   | Recombinant DBL\(\alpha\) domain          | Plasma samples from most children recognised recombinant PfEMP1 and protection against malaria.                                                                                                                    |
|                  |                         |                |              |                                            | No association between IgG to recombinant PfEMP1 and protection against malaria.                                                                                                                              |
| Kilifi, Kenya     | Mackintosh et al. [289] | Children       | <10 years    | Recombinant A4 PfEMP1 domains             | Anti-DBL\(\alpha\) antibodies in those who were parasite negative at baseline were associated with protection against malaria.                                                                                         |
|                  |                         |                |              |                                            | No association between antibodies to other domains and protection against malaria.                                                                                                                             |
| Sudan            | Staalsoe et al. [252]   | Children       | –            | Synthetic peptides to conserved regions of PfEMP1 (same epitope as Dodoo et al. 2001) | IgG levels higher in asymptomatic infection compared to febrile malaria.                                                                                                                                        |
| Tanga, Tanzania  | Magistrado et al. [290] | Children       | 0–19 years   | Recombinant DBL\(\alpha\), DBL\(2\gamma\), CIDR\(2\beta\) (3D7) | In children (4–9 years), the presence of antibodies were associated with reduced numbers of malaria episodes.                                                                                                  |
| Kilifi, Kenya     | Chan et al. [102]       | Children (296) | 1–10 years   | Reference parasites (3D7, E8B) and genetically-modified parasites | PfEMP1 is a dominant target of antibodies and PfEMP1-specific antibodies were associated with protection against symptomatic malaria.                                                                                       |

PubMed was searched for studies that examined the association between acquired human antibodies to recombinant PfEMP1 and protection against malaria, without an exclusion criterion, and attempts were made to include most studies.

\(^a\) Antibodies were measured by ELISA except for Chan et al. where antibodies were measured to native PfEMP1 by flow cytometry.

\(^b\) Not all findings are listed for all studies.
Furthermore, they complement the finding that immunity to severe disease may be rapidly acquired after several infections [197].

Others have reported that while sera from Gabonese adults recognised most of the recombinant PfEMP1 based on the DBLα region, sera from children were less reactive to the different variants [248]. Interestingly, they also showed that antibodies from highly reactive adults chosen from previous assays were capable of recognising synthetic peptides based on conserved regions of DBLα [248], suggesting that antibodies to both variant-specific and conserved regions of PfEMP1 are co-acquired. Similarly, serum antibodies from Ghanian [239] and Sudanese [249] children recognised a recombinant peptide derived from a conserved epitope of the DBLα domain, with higher antibody levels observed in asymptomatic individuals compared to those with febrile malaria suggesting that antibodies against conserved epitopes of PfEMP1 may play a role in protective immunity. However, there was no association observed between these antibodies and protection from malaria in Ghanian children, because the recombinant peptide originated from a domain that is inaccessible to antibodies [239]. Since conserved epitopes are not consistent with being key antibody targets, the role of these antibodies in protective immunity remains unclear. Few studies have evaluated the protective effect of anti-PfEMP1 antibodies (studies summarised in Table 2) and results have been inconsistent. A longitudinal study with Ghanian children did not find a correlation between protection and antibodies to the DBLα domain of PfEMP1 [239]. No protective association was observed with antibodies to the recombinant PfEMP1 domains derived from the A4 parasite line [250].

Quantifying the importance of different VSAs as targets of human antibodies is important for understanding immunity to malaria, but has been challenging to achieve. Recently, we developed a novel approach using genetically modified *P. falciparum* with inhibited PfEMP1 expression to evaluate the significance of PfEMP1 and other antigens as targets of acquired antibodies [102]. Suppressed PfEMP1 surface expression was achieved by the transfection of *P. falciparum* with a construct that encodes a *var* promoter without a downstream *var* gene [100, 101]. During in vitro culture with drug-selectable markers, the *var* promoter is expressed, which causes the silencing of all the other endogenous *var* promoters and thus suppresses PfEMP1 expression [100, 101] (Fig. 2). This approach was applied to human studies in Kenya to quantify serum antibodies to VSAs. We found that among malaria-exposed individuals, IgG binding to the surface of erythrocytes infected with the transgenic parasites was markedly reduced compared to that seen with parental parasites expressing PfEMP1. This suggests that the majority of the acquired human antibody response to the IE surface targets PfEMP1, while other VSAs appear to play a minor role as antibody targets. Our longitudinal studies further showed that individuals with PfEMP1-specific antibodies had a reduced risk of symptomatic disease while antibodies to other VSAs were not associated with protective immunity. Together, our findings demonstrate the significance of PfEMP1 as a major target of humoral immunity to malaria [102].

**Human antibodies to RIFIN and STEVOR**

Data suggest that RIFIN and STEVOR may play significant roles as targets of malaria immunity; however, they have been little studied compared to PfEMP1. In an area of intense malaria transmission in Gabon, high levels of antibodies to recombinant RIFIN were detected in a majority of the adult population. Although RIFIN antibodies were also detected in children, the prevalence of these antibodies was much lower [179]. Despite the high copy number of *rif* genes, most adult sera were capable of recognising more than one RIFIN variant suggesting the generation of a large anti-RIFIN repertoire. In addition, elevated levels of RIFIN antibodies were associated with rapid parasite clearance in children [251]. Longitudinal studies with these children showed that although RIFIN antibodies were not correlated with a reduced rate of reinfection, RIFIN antibodies were long lived (~2 years) [251]. Furthermore, higher levels of RIFIN antibodies were detected in asymptomatic children than in those with severe disease, suggesting a protective effect of these antibodies [251].

The preadsorption of immune sera on recombinant RIFIN resulted in a marked reduction in the overall antibody reactivity to the IE surface [252]. This study proposed that in addition to PfEMP1, RIFIN is a key contributor to the overall anti-VSA response [252]. Others have shown that severe malaria patients in Ghana had substantially higher antibody levels to recombinant RIFIN than asymptomatic controls, suggesting the effect of antibody boosting during a malaria episode [253].

Little has been done on naturally acquired antibodies to STEVOR. Adult plasma had elevated levels of STEVOR antibodies suggesting the immunogenicity of STEVOR during a natural infection [254]. A longitudinal study with 9-month-old infants found no correlation between STEVOR antibodies and protective immunity, but revealed an increase in the frequency of parasitaemic episodes in those with high levels of antibodies [254]. The explanation for this observation remains unclear, but it is speculated that STEVOR is not involved in mediating immunity and acts as a marker of malaria exposure instead [254]. Further studies are necessary to elucidate the importance of antibodies against native STEVOR to fully understand its biological role. As noted above, our study using parasites with
Surface antigens of *Plasmodium falciparum*-infected erythrocytes

suppressed PfEMP1 expression demonstrated that PfEMP1 is the dominant target of human antibodies. However, a proportion of antibody reactivity to the transgenic parasites was observed, suggesting that antibodies to other vSAs, such as RIFIN and STEVOR, may still play an important role in immunity [102].

**Function of antibodies to vSAs**

The mechanism by which antibodies to vSAs mediate protective immunity is only partially understood. Antibodies targeting vSAs are also thought to confer protection by interfering with IE sequestration or rosetting, features that contribute to malaria pathogenesis [79, 255]. Immune sera from infected *Aotus* monkeys blocked the binding of IEs to endothelial cells [18, 256]. Serum samples from pregnant women were capable of inhibiting IE adhesion to CSA [156, 257–259] and these antibodies were associated with improved birth outcomes in some studies [58, 260, 261]. In contrast, few studies have addressed adhesion inhibition in non-pregnant individuals. Convalescent serum from PNG children with symptomatic malaria inhibited the binding of homologous isolates to melanoma cells [230]. Antibodies from immune African adults inhibited the binding of a recombinant PfEMP1 domain to ICAM-1 [262]. Taken together, these results suggest the importance of antibodies that inhibit adhesion. Plasma antibodies from children presenting with mild malaria were capable of disrupting rosette formation in vitro, whereas those from children with severe malaria could not, suggesting that acquired antibodies are protective through rosette inhibition [79, 80, 150]. Furthermore, polyclonal antibodies against recombinant PfEMP1 domains disrupted existing rosettes and inhibited the formation of new rosettes [263].

Antibodies to vSAs also play a role in opsonising IEs for phagocytosis, an important mechanism of parasite clearance [264, 265]. A study with pregnant Malawian women showed that high levels of opsonising antibodies targeting vSAs correlated with parasite clearance and a decreased risk of maternal anaemia [266]. Immunisation of rabbits with recombinant PfEMP1 domains generated antibodies capable of inducing the opsonic phagocytosis of IEs [263]. Studies have also found that co-infection with HIV impaired the opsonic activity of antibodies for phagocytosis, thus leading to an increased risk of clinical malaria [267, 268]. Our recent data further identified PfEMP1 as a major target of naturally acquired antibodies that function to opsonise IEs for phagocytic clearance [102]. Individuals with high levels of antibodies to native PfEMP1 expressed on the IE surface promoted opsonic phagocytosis activity compared to transgenic parasites with inhibited PfEMP1 expression [102].
Vaccine studies on PfEMP1

The importance of PfEMP1 as an immune target strongly supports the development of PfEMP1 as a major vaccine candidate. However, a major challenge to its development as a vaccine is substantial antigenic diversity. Studies with animal models have provided evidence that recombinant PfEMP1 is capable of mounting a protective immune response. Immunisation of Aotus monkeys with the CIDRα domain of PfEMP1 protected against a lethal parasite challenge with the homologous, but not the heterologous parasite strain [269]. To overcome the variant-specific limitations of PfEMP1 antibodies, studies have used different combinations of PfEMP1 domains to elicit a broader antibody response. Mice immunised with a combination of CIDRα domains developed antibodies capable of agglutinating IEs using various parasite lines [270, 271]. Using an in vivo model of P. falciparum IE sequestration, rats immunised with diverse NTS-DBLα domains induced protective antibodies that reduced IE sequestration [272]. This was supported by a recent study in The Netherlands where naive volunteers, who were infected with P. falciparum, generated cross-reactive antibodies that recognised PfEMP1 from different parasite genomes [273]. Taken together, these studies suggest that it may be possible to induce sufficient cross-reactive antibodies to protect against several PfEMP1 variants, provided that the specific combinations of domains are known. A recent study further demonstrated that rabbits immunised with different recombinant proteins based on the extracellular domains of PfEMP1 recognised native PfEMP1 on intact IEs [263]. These antibodies were also capable of inhibiting rosette formation and promoting the opsonic phagocytosis of IEs [263], suggesting that the inclusion of multiple domains is necessary for effective immunity.

Research efforts on PfEMP1-specific vaccines have centred on the DBLα domain because it is one of the most conserved domains of PfEMP1 and is involved in rosetting [274]. Immunisation of rats with recombinant protein based on the DBLα domain induced antibodies that recognised conserved PfEMP1 peptides [275]. However, these antibodies were not reactive towards the IE surface of intact, mature trophozoites or towards full-length PfEMP1 from different laboratory strains [275]. They were also unable to agglutinate different parasite lines or disrupt rosette formation [275]. Antibodies against recombinant DBLα were reported to inhibit rosette formation in another study [276]. The discrepancy between these two studies [275, 276] may be reflected by different methods of protein expression as the latter, but not the former, utilised protein refolding techniques to obtain conformational-dependent epitopes that may be necessary for antibody recognition [276]. Moreover, antibodies induced by a recombinant mini-PfEMP1 (DBLα-TM-ATS) disrupted preformed rosettes and prevented in vivo sequestration [277]. The importance of the DBLα domain was further supported by the marked reduction in IE sequestration in DBLα-immunised animal models [278].

The PfEMP1 variant, VAR2CSA, is a vaccine candidate for protection against malaria in pregnancy. High levels of antibodies to multiple VAR2CSA domains in acquired pregnant women through natural exposure were associated with reduced placental infection with P. falciparum [279, 280] in some studies. Furthermore, antibodies generated against full-length [160, 281] and single domains of VAR2CSA [282] by immunisation inhibited adhesion of IEs to CSA, suggesting that vaccine-induced antibodies may have a protective function in vivo.

A major obstacle in the development of PfEMP1 as a vaccine against P. falciparum malaria is its substantial level of antigenic diversity. Several strategies can be pursued as an approach to overcome antigenic diversity (reviewed in [283]; Fig. 3). One approach would be to develop a multivalent PfEMP1 vaccine that can induce a broad repertoire of antibodies against most variants. A priority of this approach would be to determine the extent of diversity in PfEMP1 and define a combination of PfEMP1 variants that is needed to generate a broad immune response (Table 3). This approach has been used successfully with the merozoite protein apical membrane antigen 1 to overcome antigenic diversity [284, 285]. Another approach would be to target conserved epitopes of PfEMP1 such that induced antibodies may recognise most PfEMP1 variants expressed. However, identifying conserved epitopes exposed on the IE surface and understanding the tertiary/quaternary structure of PfEMP1 remains highly challenging. Further studies and innovative approaches to target antibody responses towards conserved PfEMP1 epitopes are needed. Studies have demonstrated that naturally acquired cross-reactive antibodies do occur [232, 233] and can be induced by immunisation [271]. Additionally, defining effector mechanisms of PfEMP1 immunity and creating a reference panel of parasite isolates for the evaluation of vaccine candidates must be a priority. Of further importance is a detailed knowledge of the acquisition, boosting and maintenance of antibodies to PfEMP1, as this will impact on vaccine efficacy and durability, but only limited data are currently available. Ideally, malaria vaccines would induce long-lived protection via immune responses that were sustained for an extended period after vaccination and boosted after exposure. One study suggested that antibodies to some VSAs may be short-lived, whereas other responses are sustained [286]. A recent study in pregnant women suggested that antibodies to VAR2CSA may be maintained for several decades, whereas antibodies to merozoite antigens declined more quickly [287]. The durability of vaccine-induced immune
Surface antigens of Plasmodium falciparum-infected erythrocytes

Fig. 3 Approaches to overcome antigenic diversity of PfEMP1 in vaccine development. Antigenic diversity is the major challenge to developing PfEMP1 as a vaccine against malaria. The flow chart provides an overview of the two broad approaches to overcoming antigenic diversity in PfEMP1 and the steps involved in progressing vaccine candidates to the clinical trial stage. One approach is to develop a multivalent vaccine comprised of a mixture of common PfEMP1 variants that induces a broad repertoire of antibodies. A second approach is to identify conserved epitopes on PfEMP1 and develop a vaccine that targets these epitopes to induce broadly cross-reactive antibodies. As discussed in the text, there are significant challenges to overcome for each approach. It is likely that any PfEMP1 candidate vaccine antigen(s) would be included in a multi-antigen approach that includes antigens from other parasite life stages to ensure the development of a highly effective vaccine.

Table 3 Research priorities for the development of PfEMP1 vaccines

| General priorities | Development of a multivalent vaccine | Development of a vaccine targeting conserved epitopes |
|--------------------|--------------------------------------|------------------------------------------------------|
| Define effector mechanisms of PfEMP1 immune responses and quantify their importance | Determine the extent of local/global antigenic diversity in PfEMP1 | Understand the tertiary and quaternary structure of PfEMP1 |
| Understand how antibodies to PfEMP1 are acquired, boosted and maintained over time | Understand the evolution of diversity that may lead to vaccine escape | Identify conserved epitopes exposed on the surface of IEs |
| Define antigenically conserved and diverse regions of PfEMP1 | Define the number of variants/domains to be included | Create innovative approaches/technologies for identifying and targeting conserved epitopes |
| Create a reference panel of isolates for testing/evaluating vaccine candidates | Identify specific domains of PfEMP1 for possible vaccine inclusion | |

Responses is not well known, but is an important issue for the development of highly efficacious vaccines against malaria (Table 3).

It is likely that a highly effective malaria vaccine will require a multi-antigen, multi-stage approach. Therefore, it is anticipated that any PfEMP1-based vaccine antigens would have to be included as part of a vaccine containing antigens from other stages of the parasite life cycle, such as merozoite antigens to enhance blood-stage immunity and circumsporozoite protein for induction of pre-erythrocytic responses.
immunity, and the inclusion of gametocyte antigens for transmission-blocking immunity. We suggest that after lead PfeMP1-based vaccine antigens have been identified and prioritised, they will then need to be evaluated in combination with other vaccine antigens before proceeding further to clinical trials.

Conclusion

Understanding the targets and mechanisms of human immunity is crucial for informing and advancing the development of highly effective malaria vaccines and for developing tools for measuring immunity and exposure in populations to help evaluate the impact of malaria control interventions and identify populations at risk of malaria. Multiple studies in different populations now provide strong evidence that IE surface antigens, or VSAs, are important targets of acquired protective immunity. The most important of these antigens is PfeMP1, which is a major virulence factor enabling vascular adhesion and sequestration of IEs. Studies are beginning to identify specific variants of PfeMP1 that may be common in populations or linked to disease pathogenesis and that may be targeted in vaccine development. However, there are still major gaps in our knowledge on this topic, and these are important questions for future research. Little is known about other known or proposed surface antigens and their significance as targets of immunity and new strategies, and approaches are needed to clearly define their significance in immunity. Similarly, knowledge on surface antigens of IEs with P. vivax, the second major cause of malaria, is very limited. The role of surface antigens on gametocyte-IEs needs to be determined, as antibodies to these antigens may help clear gametocyte-IEs and thereby reduce malaria transmission; currently there is great interest globally in transmission-blocking vaccines, but there are few strong candidates in development. A greater understanding of effector mechanisms that mediate immunity is needed, including both humoral and cell-mediated responses, and additional assays to measure antibody functional activity in studies of acquired immunity and in vaccine trials would be valuable. Finally, strategies to overcome antigenic diversity in PfeMP1 would provide an exciting new opportunity in malaria vaccine development.

Acknowledgments

Thank you to Christine Langer for providing the scanning electron microscopy image of an infected erythrocyte and to Campbell Aitken for helpful comments on the manuscript. The authors gratefully acknowledge funding from the National Health and Medical Research Council of Australia (Fellowship, programme grant and project grant to J. Beeson; infrastructure support scheme), the Australian Research Council (Future Fellowship to J. Beeson), the Australian Government (Australian Postgraduate Award to J. Chan) and the Victorian Operational Infrastructure Support Program.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Elliott SR, Beeson JG (2008) Estimating the burden of global mortality in children aged < 5 years by pathogen-specific causes. Clin Infect Dis 46:1794–1795
2. Miller LH, Baruch DI, Marsh K, Doumbo OK (2002) The pathogenic basis of malaria. Nature 415:673–679. doi:10.1038/415673a
3. Beeson JG, Brown GV (2002) Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cell Mol Life Sci 59:258–271
4. Chang K-H, Stevenson MM (2004) Malarial anaemia: mechanisms and implications of insufficient erythropoiesis during blood-stage malaria. Int J Parasitol 34:1501–1516. doi:10.1016/j.ijpara.2004.10.008
5. Leech JH, Barnwell JW, Miller LH, Howard RJ (1984) Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes. J Exp Med 159:1567–1575
6. Cheng Q, Cloonan N, Fischer K et al (1998) stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol 97:161–176
7. Kyes SA, Rowe JA, Kriek N, Newbold CI (1999) Rifins: a second family of clonally variant proteins expressed on the surface of red cells infected with Plasmodium falciparum. Proc Natl Acad Sci USA 96:9333–9338
8. Fernandez V, Hommel M, Chen Q et al (1999) Small, clonally variant antigens expressed on the surface of the Plasmodium falciparum-infected erythrocyte core by the rif gene family and are a target of human immune responses. J Exp Med 190:1393–1404
9. Kaviratne M, Khan SM, Jarra W, Preiser PR (2002) Small variant STEVOR antigen is uniquely located within Maurer’s clefts in Plasmodium falciparum-infected red blood cells. Eukaryot Cell 1:926–935
10. Blythe JE, Yan Yam X, Kuss C et al (2008) Plasmodium falciparum STEVOR proteins are highly expressed in patient isolates and located in the surface membranes of infected red blood cells and the apical tips of merozoites. Infect Immun 76:3329–3336. doi:10.1128/IAI.01460-07
11. Niang M, Yam XY, Preiser PR (2009) The Plasmodium falciparum STEVOR multigene family mediates antigenic variation of the infected erythrocyte. PLoS Pathog 5:e1000307
12. Winter G, Kawai S, Haeggstro¨m M et al (2005) SURFIN is a polymorphic antigen expressed on Plasmodium falciparum merozoites and infected erythrocytes. J Exp Med 201:1853–1863. doi:10.1084/jem.20041392
13. Lavazec C, Sanyal S, Templeton TJ (2006) Hypervariability within the Rifin, Stevor and Pmic-2TM superfamilies in Plasmodium falciparum. Nucleic Acids Res 34:6696–6707. doi:10.1093/nar/gkl942
14. Sam-Yellowe TY, Florens L, Johnson JR et al (2004) A Plasmodium gene family encoding Maurer’s cleft membrane proteins: structural properties and expression profiling. Genome Res 14:1052–1059
15. Winograd E, Sherman IW (2004) Malaria infection induces a conformational change in erythrocyte band 3 protein. Mol Biochem Parasitol 138:83–87. doi:10.1016/j.molbiopara.2004.07.008
16. Sherman IW, Crandall IE, Guthrie N, Land KM (1995) The sticky secrets of sequestration. Parasitol Today (Regul Ed) 11:378–384
17. MacPherson GG, Warrell MJ, White NJ et al (1985) Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 119:385–401
18. Udeinya IJ, Schmidt JA, Aikawa M et al (1981) Falciparum malaria-infected erythrocytes specifically bind to cultured human endothelial cells. Science 213:555–557
19. Looareesuwan S, Merry AH, Phillips RE et al (1987) Reduced erythrocyte survival following clearance of malarial parasitemia in Thai patients. Br J Haematol 70:5412–5415
20. Langreth SG, Peterson E (1985) Pathogenicity, stability, and immunogenicity of a knobless clone of Plasmodium falciparum in Columbian owl monkeys. Infect Immun 7:760–766
21. Pye D, O’Brien CM, Franchina P et al (1994) Plasmodium falciparum infection of splenectomized and intact Guayan Saimiri monkeys. J Parasitol 80:558–562
22. Aikawa M (1988) Human cerebral malaria. Am J Trop Med Hyg 39:3–10
23. Pongponratn E, Riganti M, Punpoowong B, Aikawa M (1991) Microvascular sequestration of parasitized erythrocytes in human falciparum malaria: a pathological study. Am J Trop Med Hyg 44:168–175
24. Beeson JG, Amin N, Kanjala M, Rogerson SJ (2002) Selective accumulation of mature asexual stages of Plasmodium falciparum-infected erythrocytes in the placenta. Infect Immun 70:5412–5415
25. Walter PR, Garin Y, Blot P (1982) Placental pathologic changes in malaria. A histologic and ultrastructural study. Am J Pathol 109:330–342
26. Trager W, Rudzinska MA, Bradbury PC (1966) The fine structure of Plasmodium falciparum and its host erythrocytes in natural malarial infections in man. Bull World Health Organ 35:883–885
27. Kilejian A (1979) Characterization of a protein correlated with the production of knob-like protrusions on membranes of erythrocytes infected with Plasmodium falciparum. Proc Natl Acad Sci USA 76:4650–4653
28. Gruenberg J, Allred DR, Sherman IW (1983) Scanning electron microscopy-analysis of the protrusions (knobs) present on the surface of Plasmodium falciparum-infected erythrocytes. J Cell Biol 97:795–802
29. Pologe LG, Pavlovec A, Shio H, Ravetch JV (1987) Primary structure and subcellular localization of the knob-associated histidine-rich protein of Plasmodium falciparum. Proc Natl Acad Sci USA 84:7139–7143
30. Culvenor JG, Langford CJ, Crewther PE et al (1987) Plasmodium falciparum: identification and localization of a knob protein antigen expressed by a cDNA clone. Exp Parasitol 63:58–67
31. Hadley TJ, Leech JH, Green TJ et al (1983) A comparison of knobby (K+) and knobless (K−) parasites from two strains of Plasmodium falciparum. Mol Biochem Parasitol 9:271–278
32. Leech JH, Barnwell JW, Aikawa M et al (1984) Plasmodium falciparum malaria: association of knobs on the surface of infected erythrocytes with a histidine-rich protein and the erythrocyte skeleton. J Cell Biol 98:1256–1264
33. Pasloske BL, Baruch DI, Scheidig C et al (1999) Identification of a region of PfeMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence. Blood 90:3766–3775
34. Crabb BS, Cooke BM, Reeder JC et al (1997) Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. Cell 89:287–296
35. Reeder JC, Cowman AF, Davern KM et al (1999) The adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum-infected erythrocytes. J Clin Invest 84:765–772. doi:10.1172/JCI114234
36. Berendt AR, Simmons DL, Tansey J et al (1999) Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum. Nature 341:57–59. doi:10.1038/341057a0
37. Baruch DI, Ma XC, Singh HB et al (1997) Identification of a receptor for human placental infection. Proc Natl Acad Sci USA 97:1766–1771. doi:10.1073/pnas.040545897
38. Reeder JC, Cowman AF, Davern KM et al (1999) The adhesion of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. Proc Natl Acad Sci USA 96:5198–5202
39. Buffet PA, Gamain B, Scheidig C et al (1999) Plasmodium falciparum gene encoding PFEEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82:77–87
40. Baruch DI, Pasloske BL, Singh HB et al (1995) Cloning the P. falciparum gene encoding PFEEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82:77–87
41. Cooke BM, Crabb BS, Reeder JC et al (1997) Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. Cell 89:287–296
42. Sherman JW, Eda S, Winograd E (2005) Cytoadherence and sequestration in Plasmodium falciparum: defining the ties that bind. Microbes Infect 5:897–909
43. Pasloske BL, Baruch DI, van Schravendijk MR et al (1993) Reduced malarial erythrocyte sequestration. Mol Biochem Parasitol 59:59–72
44. Rowe JA, Barnwell JW, Rock EP et al (1988) Two approximately 300 kilodalton Plasmodium falciparum proteins at the surface membrane of infected erythrocytes. Mol Biochem Parasitol 27:207–223
45. Kilejian A, Rashid MA, Parra M, Yang YF (1991) Sequence of the knob protein of Plasmodium falciparum recognized by a monoclonal antibody. Mol Biochem Parasitol 48:231–233
46. Pei X, An X, Guo X et al (2005) Structural and functional studies of interaction between Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and erythrocyte spectrin. J Biol Chem 280:31166–31171. doi:10.1074/jbc.M505298200
47. Deitsch KW, Wellems TE (1996) Membrane modifications in erythrocytes parasitized by Plasmodium falciparum. Mol Biochem Parasitol 76:1–10
48. Glenister FK, Coppel RL, Cowman AF et al (2002) Contribution of parasite proteins to altered mechanical properties of malaria-infected red blood cells. Blood 99:1060–1063
49. Buffet PA, Gamain B, Scheidig C et al (1999) Identification of a knob protein, PfeMP3. Mol Biochem Parasitol 59:59–72
50. Rowe JA, Barnwell JW, Rock EP et al (1988) Two approximately 300 kilodalton Plasmodium falciparum proteins at the surface membrane of infected erythrocytes. Mol Biochem Parasitol 27:207–223
53. Ockenhouse CF, Tegoshi T, Maeno Y et al (1992) Human vascular endothelial cell adhesion receptors for Plasmodium falciparum-infected erythrocytes: roles for endothelial leukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. J Exp Med 176:1183–1189

54. McCormick CJ, Craig A, Roberts D et al (1997) Intercellular adhesion molecule-1 and CD36 synergize to mediate adhesion of Plasmodium falciparum-infected erythrocytes to cultured human microvascular endothelial cells. J Clin Invest 100:2521–2529. doi:10.1122/jci119794

55. Rowe JA, Claessens A, Corrigan RA, Arman M (2009) Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol Med 11:e16. doi:10.1017/S14623994090001082

56. Beeson IG, Brown GV, Molyneux ME et al (1999) Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. J Infect Dis 180:464–472. doi:10.1086/314899

57. Beeson IG, Rogerson SJ, Elliott SR, Duffy MF (2005) Targets of protective antibodies to malaria during pregnancy. J Infect Dis 192:1647–1650. doi:10.1086/496895

58. Beeson IG, Duffy PE (2005) The immunology and pathogenesis of malaria during pregnancy. Curr Top Microbiol Immunol 297:187–227

59. Rogerson SJ, Chaiyaroj SC, Ng K et al (1995) Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes. J Exp Med 182:15–20

60. Fried M, Duffy PE (1996) Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 272:1502–1504

61. Beeson IG, Rogerson SJ, Brown GV (2002) Evaluating specific adhesion of Plasmodium falciparum-infected erythrocytes to immobilised hyaluronic acid with comparison to binding of mammalian cells. Int J Parasitol 32:1245–1252

62. Beeson IG, Rogerson SJ, Cooke BM et al (2000) Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria. Nat Med 6:86–90. doi:10.1038/71582

63. Beeson IG, Brown GV (2004) Plasmodium falciparum-infected erythrocytes demonstrate dual specificity for adhesion to hyaluronic acid and chondroitin sulfate A and have distinct adhesive properties. J Infect Dis 189:169–179. doi:10.1086/380975

64. Barfod L, Dalgaard MB, Pleman ST et al (2011) Evasion of Plasmodium falciparum infection is associated with disease outcome. PLoS ONE 6:e14741. doi:10.1371/journal.pone.0014741

65. Rowe JA, Kyes SA, Rogerson SJ et al (1999) Cytoadherence characteristics of Plasmodium falciparum-infected erythrocytes from Malawian children with severe and uncomplicated malaria. Am J Trop Med Hyg 61:467–472

66. Roberts DD, Sherwood JA, Spitalnik SL et al (1985) Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature 318:64–66

67. Treutiger CJ, Hedlin I, Helmby H et al (1990) Human cerebral malaria: association with cytoadherence and lack of anti-rosetting antibodies. Lancet 336:1457–1460

68. Treutiger CJ, Hedlund I, Helmby H et al (1991) Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria. Am J Trop Med Hyg 46:503–510

69. Beeson IG, Obeire J, Newbold CI, Marsh K (1995) Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun 63:2323–2326

70. Rowe JA, Kyes SA, Rogerson SJ et al (2002) Identification of a conserved Plasmodium falciparum var gene implicated in malaria in pregnancy. J Infect Dis 185:1207–1211. doi:10.1086/339684

71. Schena MP, Schena MO, Livak KJ et al (1995) High levels of Plasmodium falciparum rosetting in clinical forms of severe malaria in African children. Am J Trop Med Hyg 61:467–472

72. Prasad SK, Rama M, Rao P et al (2002) Rosetting. Parasitol Today (Regul Ed) 10:73–79

73. Roberts DD, Sherwood JA, Spitalnik SL et al (1985) Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature 318:64–66

74. Treutiger CJ, Hedlin I, Helmby H et al (1991) Rosette formation in Plasmodium falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or uncomplicated malaria. Am J Trop Med Hyg 46:503–510

75. Rowe JA, Kyes SA, Rogerson SJ et al (2002) Identification of a conserved Plasmodium falciparum var gene implicated in malaria in pregnancy. J Infect Dis 185:1207–1211. doi:10.1086/339684

76. Schena MP, Schena MO, Livak KJ et al (1995) High levels of Plasmodium falciparum rosetting in clinical forms of severe malaria in African children. Am J Trop Med Hyg 61:467–472

77. Robins-Browne RM, Craig AG, Berendt AR et al (1992) Rapid switching of Plasmodium falciparum rosetting antibodies. Lancet 340:812–819

78. Wahlgren M, Fernandez V, Scholander C, Carlson J (1994) Rosetting. Parasitol Today (Regul Ed) 10:73–79

79. Carlson J, Helmby H, Hill AV et al (1990) Human cerebral malaria: association with cytoadherence and lack of anti-rosetting antibodies. Lancet 336:1457–1460

80. Robins-Browne RM, Craig AG, Berendt AR et al (1992) Rapid switching of Plasmodium falciparum rosetting antibodies. Lancet 340:812–819

81. Robins-Browne RM, Craig AG, Berendt AR et al (1992) Rapid switching of Plasmodium falciparum rosetting antibodies. Lancet 340:812–819

82. Rowe JA, Obeire J, Newbold CI, Marsh K (1995) Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun 63:2323–2326

83. Rowe JA, Kyes SA, Rogerson SJ et al (2002) Identification of a conserved Plasmodium falciparum var gene implicated in malaria in pregnancy. J Infect Dis 185:1207–1211. doi:10.1086/339684

84. Schena MP, Schena MO, Livak KJ et al (1995) High levels of Plasmodium falciparum rosetting in clinical forms of severe malaria in African children. Am J Trop Med Hyg 61:467–472

85. Chen Q, Barragan A, Fernandez v et al (1998) Identification of sera from Gambians with cerebral or uncomplicated malaria. Am J Trop Med Hyg 81:987–993. doi:10.4269/ajtmh.2009.09-0406

86. al-Yaman F, Genton B, Mokela D et al (1995) Human cerebral malaria: lack of significant association between cytoadherence and disease severity. Trans R Soc Trop Med Hyg 89:55–58

87. Chen Q, Barragan A, Fernandez V et al (1998) Identification of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) as the rosetting ligand of the malaria parasite P. falciparum. J Exp Med 187:15–23

88. Roberts DD, Sherwood JA, Spitalnik SL et al (1985) Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature 318:64–66

89. Pain A, Ferguson DJ, Kai O et al (2001) Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc Natl Acad Sci USA 98:1805–1810. doi:10.1073/pnas.98.4.1805
Surface antigens of *Plasmodium falciparum*-infected erythrocytes

89. Chotivanich K, Sritabal J, Udomsangpetch R et al (2004) Platelet-induced autoagglutination of *Plasmodium falciparum*-infected red blood cells and disease severity in Thailand. J Infect Dis 189:1052–1055. doi:10.1086/381900
90. McMorrán BJ, Marshall VM, de Graaf C et al (2009) Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 323:797–800
91. McMorrán BJ, Wieczorski L, Drysdale KE et al (2012) Platelet factor 4 and Duffy antigen required for platelet killing of *Plasmodium falciparum*. Science 338:1348–1351. doi:10.1126/ science.1228892
92. Bull PC, Lowe BS, Kortok M, Marsh K (1999) Antibody recognition of *Plasmodium falciparum* erythrocyte surface antigens in Kenya: evidence for rare and prevalent variants. Infect Immun 67:733–739
93. Piper KP, Roberts DJ, Day KP (1999) *Plasmodium falciparum*: analysis of the antibody specificity to the surface of the trophozoite-infected erythrocyte. Exp Parasitol 91:161–169. doi:10.1006/expr.1998.4368
94. Howard RJ, Barnwell JW, Kao V (1983) Antigenic variation of *Plasmodium knowlesi* malaria: identification of the variant antigen on infected erythrocytes. Proc Natl Acad Sci USA 80:4129–4133
95. al-Khedery B, Barnwell JW, Galinski MR (1999) Antigenic variation in malaria: a 3′ genomic alteration associated with the expression of a P. knowlesi variant antigen. Mol Cell 3:131–141
96. Korir CC, Galinski MR (2006) Proteomic studies of *Plasmodium falciparum* erythrocyte surface antigens. Cell 122:981–992
97. Voss TS, Healer J, Marty AJ et al (2006) A large gene family for putative variant antigens shared by human malaria parasites. Proc Natl Acad Sci USA 103:7511–7516
98. Howard RJ, Barnwell JW, Kortok M, Turner CMR, Barrett MP (2004) Antigenic variation in malaria: a 3′ genomic alteration associated with the expression of a P. knowlesi variant antigen. Mol Cell 3:131–141
99. al-Khedery B, Barnwell JW, Galinski MR (1999) Antigenic variation in malaria: a 3′ genomic alteration associated with the expression of a P. knowlesi variant antigen. Mol Cell 3:131–141
100. Janssen CS, Phillips RS, Turner CMR, Barrett MP (2002) A large gene family for putative variant antigens shared by human and rodent malaria parasites. Proc Biol Sci 269:431–436. doi:10.1098/rspb.2001.1903
101. Janssen CS, Phillips RS, Turner CMR, Barrett MP (2004) *Plasmodium* interspersed repeats: the major multigene superfamily of malaria parasites. Nucleic Acids Res 32:5712–5720. doi:10.1093/nar/gkh907
102. del Portillo HA, Fernandez-Becerra C, Bowman S et al (2001) A superfamily of variant genes encoded in the subtelomeric region of *Plasmodium vivax*. Nature 410:839–842. doi:10.1038/35071118
103. Janssen CS, Barrett MP, Turner CMR, Phillips RS (2002) A large gene family for putative variant antigens shared by human and rodent malaria parasites. Proc Biol Sci 269:431–436. doi:10.1098/rspb.2001.1903
104. Garcia CR, Takeuchi M, Yoshioka K, Miyamoto H (1997) Imaging *Plasmodium falciparum*-infected ghost and parasite by atomic force microscopy. J Struct Biol 119:92–98. doi:10.1006/jsbi.1997.3886
105. Marti M (2004) Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 306:1930–1933. doi:10.1126/science.1102452
106. Hiller NL, Bhattacharjee S, van Ooj C et al (2004) A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science 306:1934–1937. doi:10.1126/science.1102737
107. de Koning-Ward TF, Gilson PR, Boddey JA et al (2009) A newly discovered protein export machine in malaria parasites. Nature 459:945–949. doi:10.1038/nature08104
108. Crabb BS, de Koning-Ward TF, Gilson PR (2010) Protein export in *Plasmodium* parasites: from the endoplasmic reticulum to the vacuolar export machine. Int J Parasitol 40:509–513. doi:10.1016/j.ijpara.2010.02.002
109. Mantel P-Y, Hoang AN, Goldowitz I et al (2013) Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. Cell Host Microbe 13:521–534. doi:10.1016/j.chom.2013.04.009
110. Regev-Rudzki N, Wilson DW, Carvalho TG et al (2013) Cell–cell communication between malaria-infected red blood cells via exosome-like vesicles. Cell. doi:10.1016/j.cell.2013.04.029
111. Su XZ, Heatwole VM, Wertheimer SP et al (1995) The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes. Cell 82:89–100
112. Smith JD, Chitnis CE, Craig AG et al (1995) Switches in expression of *Plasmodium falciparum* var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82:101–110
113. Scherf A, Hernandez-Rivas R, Buffet P et al (1998) Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra-erythrocytic development in *Plasmodium falciparum*. EMBO J 17:5418–5426. doi:10.1093/emboj/17.18.5418
114. Joergensen L, Bengtsson DC, Bengtsson A et al (2010) Surface co-expression of two different PIEMP1 antigens on single *Plasmodium falciparum*-infected erythrocytes facilitates binding to ICAM1 and PECAM1. PLoS Pathog 6:e1001083. doi:10.1371/ journal.ppat.1001083
115. Kriek N, Tilley L, Horrocks P et al (2003) Characterization of the pathway for transport of the cytoadherence-mediating protein, PIEMP1, to the host cell surface in malaria parasite-infected erythrocytes. Mol Microbiol 50:1215–1227
116. Boddey JA, Cowman AF (2013) Plasmodium nesting: remodeling the erythrocyte from the inside out. Annu Rev Microbiol 67:733–739. doi:10.1146/annurev-micro-092412-155730
117. Ellsworth B, Crabb BS, Gilson PR (2014) Protein export in malaria parasites: an update. Cell Microbiol 16:355–363. doi:10.1111/cmi.12261
118. Haegggstrom M, Kironde F, Berzins K et al (2004) Common trafficking pathway for variant antigens destined for the surface of the *Plasmodium falciparum*-infected erythrocyte. Mol Biochem Parasitol 133:1–14
119. Horrocks P, Pinches RA, Chakravorty SJ et al (2005) PIEMP1 expression is reduced on the surface of knobless *Plasmodium falciparum* infected erythrocytes. J Cell Sci 118:2507–2518. doi:10.1242/jcs.02381
120. Gardner JP, Pinches RA, Roberts DJ, Newbold CI (1996) Variant antigens and endothelial receptor adhesion in *Plasmodium falciparum*. Proc Natl Acad Sci USA 93:3503–3508
121. Bilsnick T, Morales Betouille ME, Barale JC et al (2000) Plsbp1, a Maurer’s cleft *Plasmodium falciparum* protein, is associated with the erythrocyte skeleton. Mol Biochem Parasitol 111:107–121
122. Cooke BM, Buckingham DW, Glenister FK et al (2006) A Maurer’s cleft-associated protein is essential for expression of the major malaria virulence antigen on the surface of infected red blood cells. J Cell Biol 172:899–908. doi:10.1083/jcb.200509122
123. Maier AG, Rug M, O’Neill MT et al (2007) Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum-infected erythrocyte surface. Blood 109:1289–1297. doi:10.1182/blood-2006-08-043364

124. Maier AG, Rug M, O’Neill MT et al (2008) Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell 134:48–61. doi:10.1016/j.cell.2008.04.051

125. Kübler S, Charnaud S, Dagan T et al (2012) Plasmodium falciparum-encoded exported hsp70/hsp40 chaperone/co-chaperone complexes within the host erythrocyte. Cell Microbiol 14:1784–1795. doi:10.1111/j.1365-2958.2012.02180.x

126. Spycher C, Rug M, Pfaffl M et al (2008) The Maurer’s cleft protein MAHRP1 is essential for trafficking of PfEMP1 to the surface of Plasmodium falciparum-infected erythrocytes. Mol Microbiol 68:1300–1314. doi:10.1111/j.1365-2958.2008.06235.x

127. Dixon MWA, Kenny S, McMillan PJ et al (2011) Genetic ablation of a Maurer’s cleft protein prevents assembly of the Plasmodium falciparum virulence complex. Mol Microbiol 81:982–993. doi:10.1111/j.1365-2958.2011.07740.x

128. Glenister FK, Fernandez KM, Kats LM et al (2009) Functional alteration of red blood cells by a megadalan protein of Plasmodium falciparum. Blood 113:919–928. doi:10.1182/blood-2008-05-157735

129. Durasingham MT, Cowman AF (2005) Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 94:181–190. doi:10.1016/j.actatropica.2005.04.008

130. Freitas-Junior LH, Hernández-Rivas R, Ralph SA et al (2005) Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell 121:25–36. doi:10.1016/j.cell.2005.01.037

131. Tonkin CJ, Carret CK, Durasingham MT et al (2009) Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol 7:e84. doi:10.1371/journal.pbio.0070106

132. Biggs BA, Goozé L, Wycherley K et al (1991) Antigenic variation in Plasmodium falciparum. Proc Natl Acad Sci USA 88:9171–9174

133. Chen Q, Heddini A, Barragan A et al (2000) The semiconserved TK domain of the Plasmodium falciparum P. falciparum-infected host erythrocyte surface. Blood 99:1289–1297. doi:10.1182/blood-2000-08-032911

134. Voigt S, Hanspal M, LeRoy PJ et al (2000) The cytoadherence ligand Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) binds to the P. falciparum knob-associated histidine-rich protein (KAHRP) by electrostatic interactions. Mol Biochem Parasitol 110:423–428

135. Waller KL, Cooke BM, Nunomura W et al (1999) Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1). J Biol Chem 274:23808–23813

136. Rug M, Prescott SW, Fernandez KM et al (2006) The role of KAHRP domains in knob formation and cytoadherence of P. falciparum-infected human erythrocytes. Blood 108:370–378. doi:10.1182/blood-2005-11-4624

137. Chattopadhyay R, Taneja T, Chakrabarti K et al (2004) Molecular analysis of the cytoadherence phenotype of a Plasmodium falciparum field isolate that binds intercellular adhesion molecule-1. Mol Biochem Parasitol 133:255–265

138. Springer AL, Smith LM, Mackay DQ et al (2004) Functional interdependence of the DBLbeta domain and c2 region for binding of the Plasmodium falciparum variant antigen to ICAM-1. Mol Biochem Parasitol 137:55–64. doi:10.1016/j.molbiopara.2004.03.019

139. Robinson BA, Welch TL, Smith JD (2003) Widespread functional specialization of Plasmodium falciparum erythrocyte membrane protein 1 family members to bind CD36 analysed across a parasite genome. Mol Microbiol 47:1265–1278

140. Smith JD, Kyes S, Craig AG et al (1998) Analysis of adhesive domains from the A4VAR Plasmodium falciparum erythrocyte membrane protein-1 identifies a CD36 binding domain. Mol Biochem Parasitol 97:133–148

141. Srivastava A, Gangnard S, Dechavanne S et al (2011) Var2CSA minimal CSA binding region is located within the N-terminal region. PLoS ONE 6:e20270. doi:10.1371/journal.pone.0020270

142. Gardner MJ, Hall N, Fung E et al (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498–511. doi:10.1038/nature01097

143. Kraemer SM, Smith JD (2003) Evidence for the importance of genetic structuring to the structural and functional specialization of the Plasmodium falciparum var gene family. Mol Microbiol 50:1527–1538

144. Lavstsen T, Salanti A, Jensen ATR et al (2003) Sub-grouping of Plasmodium falciparum 3’D’ var genes based on sequence analysis of coding and non-coding regions. Malar J 2:27. doi:10.1186/1475-2875-2-27

145. Voss TS, Thompson JK, Waterkeyn J et al (2000) Genomic distribution and functional characterisation of two distinct and conserved Plasmodium falciparum var gene 5’ flank sequences. Mol Biochem Parasitol 107:103–115

146. Bull PC, Kyes S, Buckee CO et al (2007) An approach to classifying sequence tags sampled from Plasmodium falciparum var genes, Mol Biochem Parasitol 154:98–102. doi:10.1016/j.molbiopara.2007.03.011

147. Bull PC, Berriman M, Kyes S et al (2005) Plasmodium falciparum var gene expression is modified by host immunity. Proc Natl Acad Sci 102:21801–21806. doi:10.1073/pnas.0507941102

148. Warimwe GM, Keane TM, Fegan G et al (2009) Plasmodium falciparum var gene expression is modified by host immunity. Proc Natl Acad Sci USA 106:21801–21806. doi:10.1073/pnas.0907522106

149. Kyriacou HM, Stone GN, Challis RJ et al (2006) Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol Biochem Parasitol 153:211–216. doi:10.1016/j.molbiopara.2006.08.005

150. Falk N, Kaestli M, Qi W et al (2009) Analysis of Plasmodium falciparum var gene expression patterns during malaria. PLoS Pathog 2:e26. doi:10.1371/journal.ppat.0010026.st003

151. Rottmann M, Lavstsen T, Mugasa JP et al (2006) Differential expression of var gene groups is associated with morbidity caused by Plasmodium falciparum infection in Tanzanian children. Infect Immun 74:3904–3911. doi:10.1128/IAI.02703-05

152. Jensen ATR, Magistrado P, Sharp S et al (2004) Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J Exp Med 199:1179–1190. doi:10.1084/jem.20040274

153. Lavstsen T, Turner L, Suguji F et al (2012) Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc Natl Acad Sci. doi:10.1073/pnas.1120955110

154. Warimwe GM, Fegan G, Musyoki JN et al (2012) Prognostic indicators of life-threatening malaria are associated with distinct parasite variant antigen profiles. Sci Transl Med 4:129ra45. doi:10.1126/scitranslmed.3003247

155. Avril M, Tripathi AK, Brazier AJ et al (2012) A restricted subset of var genes mediates adherence of Plasmodium...
falciparum-infected erythrocytes to brain endothelial cells. Proc Natl Acad Sci. doi:10.1073/pnas.1120534109

156. Claessens A, Adams Y, Ghumra A et al (2012) A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells. Proc Natl Acad Sci. doi:10.1073/pnas.1120461109

157. Cham GKK, Turner L, Lusingu J et al (2009) Sequential, ordered acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 domains. J Immunol 183:3356–3363. doi:10.4049/jimmunol.0901331

158. Kaestli M, Cockburn IA, Cortés A et al (2006) Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. J Infect Dis 193:1567–1574. doi:10.1086/503776

159. Hommel M, Elliott SR et al (2010) Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women. Infect Immun 78:1963–1978. doi:10.1128/IAI.01365-09

160. Avril M, Hathaway MJ, Srivastava A et al (2011) Antibodies to a full-length VAR2CSA immunogen are broadly strain-transcendent but do not cross-inhibit different placental-type parasite isolates. PLoS ONE 6:e16622. doi:10.1371/journal.pone.0016622.t001

161. Kraemer SM, Kyes SA, Aggarwal G et al (2007) Patterns of placental malaria and have overlapping and distinct targets. J Infect Dis 196:117–124. doi:10.1086/518361

162. Duffy MF, Byrne TJ, Elliott SR et al (2005) Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype. Mol Microbiol 56:774–788. doi:10.1111/j.1365-2958.2005.04577.x

163. Salanti A, Staalsoe T, Lavstsen T et al (2003) Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 49:179–191. doi:10.1046/j.1365-2958.2003.03570.x

164. Salanti A, Dahlbäck M, Turner L et al (2004) Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200:1197–1203. doi:10.1084/jem.20041579

165. Becson JG, Andrews KT, Boyle M et al (2007) Structural basis for binding of Plasmodium falciparum erythrocyte membrane protein 1 to chondroitin sulfate and placental tissue and the influence of protein polymorphisms on binding specificity. J Biol Chem 282:22426–22436. doi:10.1074/jbc.M700231200

166. Magistrado P, Salanti A, Tuikue Ndam NG et al (2008) VAR2CSA expression on the surface of placenta-derived Plasmodium falciparum-infected erythrocytes. J Infect Dis 198:1071–1074. doi:10.1086/591502

167. Becson JG, Mann EJ, Elliott SR et al (2004) Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes and adhesion inhibitory antibodies are associated with placental malaria and have overlapping and distinct targets. J Infect Dis 189:540–551

168. Viebig NK, Gamain B, Scheidig C et al (2005) A single member of the Plasmodium falciparum var multigene family determines cytodeath to the placental receptor chondroitin sulphate A. EMBO Rep 6:775–781. doi:10.1038/sj.embor.7400466

169. Duffy MF, Maier AG, Byrne TJ et al (2006) VAR2CSA is the principal ligand for chondroitin sulfate A in two allelogenic isolates of Plasmodium falciparum. Mol Biochem Parasitol 148:117–124. doi:10.1016/j.molbiopara.2006.03.006

170. Hayward RE, Tiwari B, Piper KP et al (1999) Virulence and transmission success of the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci USA 96:4563–4568

171. Sharp S, Lavstsen T, Fivelman QL et al (2006) Programmed transcription of the var gene family, but not of stevor, in Plasmodium falciparum gametocytes. Eukaryot Cell 5:1206–1214. doi:10.1128/EC.00029-06

172. Tibárcio M, Silvestrini F, Bertuccini L et al (2012) Early gametocytes of the malaria parasite Plasmodium falciparum specifically remodel the adhesive properties of infected erythrocyte surface. Cell Microbiol. doi:10.1111/cmi.12062

173. Algaran M, Zhang R, Law SK et al (2012) Host cell deformability is linked to transmission in the human malaria parasite Plasmodium falciparum. Cell Microbiol 14:983–993. doi:10.1111/j.1462-5822.2012.01786.x

174. Kyes S, Pinches R, Newbold C (2000) A simple RNA analysis method shows var and rif multigene family expression patterns in Plasmodium falciparum. Mol Biochem Parasitol 105:311–315

175. Florens L, Washburn MP, Raine JD et al (2002) A proteomic view of the Plasmodium falciparum life cycle. Nature 419:520–526. doi:10.1038/nature01107

176. Petter M, Haeggström M, Khattab A et al (2007) Variant proteins of the Plasmodium falciparum RIFIN family show distinct subcellular localization and developmental expression patterns. Mol Biochem Parasitol 156:51–61. doi:10.1016/j.molbiopara.2007.07.011

177. Wang CW, Mwakalinga SB, Sutherland CJ et al (2010) Identification of a major rif transcript common to gametocytes and sporozoites of Plasmodium falciparum. Malar J 9:147. doi:10.1186/1475-2875-9-147

178. Joannin N, Abhimani S, Sonnhammer EL, Wahlgren M (2008) Sub-grouping and sub-functionalization of the RIFIN multi-copy protein family. BMC Genomics 9:19. doi:10.1186/1471-2164-9-19

179. Abdel-Latif MS, Khattab A et al (2002) Recognition of variant Rfinit antigens by human antibodies induced during natural Plasmodium falciparum infections. Infect Immun 70:7013–7021

180. Przyborski JM, Miller SK, Pfahler JM et al (2005) Trafficking of STEVOR to the Maurer’s clefts in Plasmodium falciparum-infected erythrocytes. EMBO J 24:2306–2317. doi:10.1038/sj.emboj.7600720

181. McRobert L, Preiser P, Sharp S et al (2004) Distinct trafficking and localization of STEVOR proteins in three stages of the Plasmodium falciparum life cycle. Infect Immun 72:6597–6602. doi:10.1128/IAI.72.11.6597-6602.2004

182. Sanyal S, Egée S, Bouyer G et al (2012) Plasmodium falciparum STEVOR proteins impact erythrocyte mechanical properties. Blood 119:e1–e8. doi:10.1182/blood-2011-08-370734

183. Mills JP, Diez-Silva M, Quinn DJ et al (2007) Effect of plasmodial RESA protein on deformability of human red blood cells harboring Plasmodium falciparum. Proc Natl Acad Sci USA 104:9213–9217. doi:10.1073/pnas.0703433104

184. Lavazec C, Sanyal S, Templeton TJ (2007) Expression switching in the stever and Pfmc-2TM superfamilies in Plasmodium falciparum. Mol Microbiol 64:1621–1634. doi:10.1111/j.1365-2958.2007.05767.x

185. García JE, Puentes A, Curtidor H et al (2005) Peptides from the Plasmodium falciparum RIFIN family show distinct subcellular localization and developmental expression patterns. Mol Biochem Parasitol 148:117–124. doi:10.1016/j.molbiopara.2006.03.006

186. Hayward RE, Tiwari B, Piper KP et al (1999) Virulence and transmission success of the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci USA 96:4563–4568
188. Mphande FA, Ribacke U, Kaneko O et al (2008) SURFIN4.1, a schizont-merozoite associated protein in the SURFIN family of Plasmodium falciparum. Malar J 7:116. doi:10.1186/1475-2875-7-116

189. Winograd E, Eda S, Sherman IW (2004) Chemical modifications of band 3 protein affect the adhesion of Plasmodium falciparum-infected erythrocytes to CD36. Mol Biochem Parasitol 136:243–248

190. Eda S, Lawler J, Sherman IW (1999) Plasmodium falciparum-infected erythrocyte adhesion to the type 3 repeat domain of thrombospondin-1 is mediated by a modified band 3 protein. Mol Biochem Parasitol 100:195–205

191. Lucas JZ, Sherman IW (1998) Plasmodium falciparum: thrombospondin mediates parasitized erythrocyte band 3-related adhesin binding. Exp Parasitol 89:78–85

192. Crandall I, Collins WE, Gysin J, Sherman IW (1993) Synthetic peptides based on motifs present in human band 3 protein inhibit cytoadherence/sequestration of the malaria parasite Plasmodium falciparum. Proc Natl Acad Sci USA 90:4703–4707

193. Langhorne J, Ndungu FM, Sponaas A-M, Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9:725–732. doi:10.1038/n.205

194. Good MF, Stanisic D, Xu H et al (2004) The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol Rev 201:254–267. doi:10.1111/j.0105-2896.2004.00178.x

195. Beeson JG, Osier FHA, van der Heyde HC, Huszar D, woodhouse C et al (1994) The relationship between anti-merozoite antibodies and protection from Plasmodium falciparum infection. Malar J 7:116.

196. Malar J 7:116. doi:10.1086/314689

197. McGregor IA (1964) Studies in the acquisition of immunity of Plasmodium falciparum. Immunol Rev 201:254–267. doi:10.1111/j.0105-2896.2004.00178.x

198. McGregor IA (1964) Studies in the acquisition of immunity of Plasmodium falciparum. Immunol Rev 201:254–267. doi:10.1111/j.0105-2896.2004.00178.x

199. Snow RW, Nahlen B, Palmer A et al (1998) Risk of severe malaria among African infants: direct evidence of clinical protection during early infancy. J Infect Dis 177:819–822

200. 5638

201. Donati D, Zhang LP, Chêne A et al (2006) Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J Immunol 177:3043–3044

202. Donati D, Zabo B, Chêne A et al (2006) Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J Immunol 177:3043–3044

203. Simoné O, Bejarano MT, Pierce SK et al (2011) TLRs innate immunoreceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1α-driven human polyclonal B cell activation. Acta Trop 119:144–150. doi:10.1016/j.actatropica.2011.05.005

204. Allsopp CEM, Sanni LA, Reutsaet L et al (2002) CD4 T cell responses to a variant antigen of the malaria parasite Plasmodium falciparum, erythrocyte membrane protein-1, in individuals living in malaria-endemic areas. J Infect Dis 185:812–819. doi:10.1086/339521

205. Ndungu FM, Sanni L, Urban BC, Ferguson DJ, Pain A et al (1999) Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400:73–77. doi:10.1038/21900

206. Elliott SR, Spurck TP, Dodin JM et al (2007) Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1. Infect Immun 75:3621–3632. doi:10.1128/IAI.00095-07

207. Artavanis-Tsakonas K, Eleme K, McQueen KL et al (2003) Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J Immunol 171:5396–5405

208. Chen Q, Amaladoss A, Ye W et al (2014) Human natural killer cells control Plasmodium falciparum infection by eliminating infected red blood cells. Clin Infect Dis 51:e50–e60. doi:10.1086/656413
infected erythrocytes to amelanotic melanoma cells. Nature 303:429–431

257. Elliott SR, Brennan AK, Beeson JG et al (2005) Placental malaria induces variant-specific antibodies of the cytophilic subtypes immunoglobulin G1 (IgG1) and IgG3 that correlate with adhesion inhibitory activity. Infect Immun 73:5903–5907. doi: 10.1128/IAI.73.9.5903–5907.2005

258. Ricke CH, Staalsoe T, Koram K et al (2000) Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. J Immunol 165:3309–3316

259. Fried M, Nosten F, Brockman A et al (1998) Maternal antibodies block malaria. Nature 395:851–852. doi: 10.1038/27570

260. Duffy PE, Fried M (2003) Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infect Immun 71:6620–6623

261. Staalsoe T, Shulman CE, Bulmer JN et al (2004) Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum. Lancet 363:283–289. doi: 10.1016/S0140-6736(03)15386-X

262. Oleinikov AV, Amos E, Frye IT et al (2009) High throughput functional assays of the variant antigen PIEMP1 reveal a single domain in the 3D7 Plasmodium falciparum genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies. PLoS Pathog 5:e1000386. doi: 10.1371/journal.ppat.1000386.g006

263. Ghumra A, Khunrae P, Ataíde R et al (2011) Immunisation with recombinant PIEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to Plasmodium falciparum. PLoS ONE 6:e16414. doi: 10.1371/journal.pone.0016414

264. Celada A, Cruchaud A, Perrin LH (1982) Opsonic activity of human immune serum on in vitro phagocytosis of Plasmodium falciparum infected red blood cells by monocytes. Clin Exp Immunol 47:635–644

265. Bouharoun-Tayoun H, Attanath P, Sabchareon A et al (1990) Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172:1633–1641

266. Feng G, Aiiken E, Yosaatmadja F et al (2009) Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy. J Infect Dis 200:299–306. doi: 10.1086/599841

267. Ataide R, Hasang W, Wilson DW et al (2010) Using an improved phagocytosis assay to evaluate the effect of HIV on specific antibodies to pregnancy-associated malaria. PLoS ONE 5:e10807. doi: 10.1371/journal.pone.0010807

268. Keen J, Serghides L, Ayi K et al (2007) HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. Plos Med 4:e181. doi: 10.1371/journal.pmed.0040181

269. Baruch DI, Gamain B, Barnwell JW et al (2002) Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc Natl Acad Sci USA 99:3860–3865. doi: 10.1073/pnas.022018399

270. Baruch DI, Gamain B, Miller LH (2003) DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses. Infect Immun 71:4536–4543

271. Gratepanche S, Gamain B, Smith JD et al (2003) Induction of crossreactive antibodies against the Plasmodium falciparum variant protein. Proc Natl Acad Sci USA 100:13307–13312. doi: 10.1073/pnas.223588100

272. Ahuja S, Pettersson F, Moll K et al (2006) Induction of cross-reactive immune responses to NTS-DBL1-alpha/x of PIEMP1 and in vivo protection on challenge with Plasmodium falciparum. Vaccine 24:6140–6154. doi: 10.1016/j.vaccine.2006.05.030

273. Turner L, Wang CW, Lavstsen T et al (2011) Antibodies against PIEMP1, RIFIN, MSP3 and GLURP are acquired during controlled Plasmodium falciparum malaria infections in naive volunteers. PLoS ONE 6:e29205. doi: 10.1371/journal.pone.0029205

274. Flick K, Chen Q (2004) var genes, PIEMP1 and the human host. Mol Biochem Parasitol 134:3–9

275. Oguarui RM, Mattei D, Tena-Tomás C et al (2003) Recombinant Duffy binding-like alpha domains of Plasmodium falciparum erythrocyte membrane protein 1 elicit antibodies in rats that recognise conserved epitopes. Parasitol Res 90:467–472. doi: 10.1007/s00436-003-0884-8

276. Mayor A, Rovira-Vallbona E, Srivastava A et al (2009) Functional and immunological characterization of a Duffy binding-like alpha domain from Plasmodium falciparum erythrocyte membrane protein 1 that mediates rosetting. Infect Immun 77:3857–3863. doi: 10.1128/IAI.00049-09

277. Chen Q, Pettersson F, Vogt AM et al (2004) Immunization with PIEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes. Vaccine 22:2701–2712. doi: 10.1016/j.vaccine.2004.02.015

278. Moll K, Pettersson F, Vogt AM et al (2007) Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain. Infect Immun 75:211–219. doi: 10.1128/IAI.00749-06

279. Tutterrow YL, Salanti A, Avril M et al (2012) High avidity antibodies to full-length VAR2CSA correlate with absence of placental malaria. PLoS ONE 7:e40049. doi: 10.1371/journal.pone.0040049

280. Tutterrow YL, Avril M, Singh K et al (2012) High levels of antibodies to multiple domains and strains of VAR2CSA correlate with the absence of placental malaria in Cameroonian women living in an area of high Plasmodium falciparum transmission. Infect Immun 80:1479–1490. doi: 10.1128/IAI.00712-12

281. Bigey P, Gridehou S, Doritchamou J et al (2011) The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. J Infect Dis 204:1125–1133. doi: 10.1086/661934

282. Nielsen MA, Pinto VV, Resende M et al (2009) Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun 77:2482–2487. doi: 10.1128/IAI.00159-09

283. Beeson JG, Chan J-A, Fowkes FJ (2013) PIEMP1 as a target of human immunity and a vaccine candidate against malaria. Expert Rev Vaccines 12:105–108. doi: 10.1586/erv.12.144

284. Drew DR, Hodder AN, Wilson DW et al (2012) Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS ONE 7:e51023. doi: 10.1371/journal.pone.0051023

285. Miura K, Herrera R, Dion A et al (2013) Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun 81:1491–1501. doi: 10.1128/IAI.01414-12

286. Kinyanjui SM, Bull P, Newbold CI, Marsh K (2003) Kinetics of antibody responses to Plasmodium falciparum-infected parasites of antibody responses to Plasmodium falciparum-infected
Surface antigens of *Plasmodium falciparum*-infected erythrocytes

- Fowkes FJI, McGready R, Johnstone-Robertson S et al (2012) Antibody boosting and longevity following tetanus immunization during pregnancy. Clin Infect Dis. doi:10.1093/cid/cis979
- Yone CLR, Kremsner PG, Luty AJF (2005) Immunoglobulin G isotype responses to erythrocyte surface-expressed variant antigens of *Plasmodium falciparum* predict protection from malaria in African children. Infect Immun 73:2281–2287. doi:10.1128/IAI.73.4.2281-2287.2005
- Mackintosh CL, Mwangi T, Kinyanjui SM et al (2008) Failure to respond to the surface of *Plasmodium falciparum* infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int J Parasitol 38:1445–1454. doi:10.1016/j.ijpara.2008.03.009
- Magistrado PA, Lusingu J, Vestergaard LS et al (2007) Immunoglobulin G antibody reactivity to a group A *Plasmodium falciparum* erythrocyte membrane protein 1 and protection from *P. falciparum* malaria. Infect Immun 75:2415–2420. doi:10.1128/IAI.00951-06

287. Bull PC, Kortok M, Kai O et al (2000) *Plasmodium falciparum*-infected erythrocytes: agglutination by diverse Kenyan plasma is associated with severe disease and young host age. J Infect Dis 182:252–259. doi:10.1086/315652

288. Cabrera G, Yone C, Tebo AE et al (2004) Immunoglobulin G isotype responses to variant surface antigens of *Plasmodium falciparum* in healthy Gabonese adults and children during and after successive malaria attacks. Infect Immun 72:284–294

289. Giha HA, Staalsoe T, Dodo D et al (1999) Overlapping antigenic repertoires of variant antigens expressed on the surface of erythrocytes infected by *Plasmodium falciparum*. Parasitology 119(Pt 1):7–17

290. Reeder JC, Rogerson SJ, al-Yaman F et al (1994) Diversity of agglutinating phenotype, cytoadherence, and rosette-forming characteristics of *Plasmodium falciparum* isolates from Papua New Guinean children. Am J Trop Med Hyg 51:45–55

291. Crompton PD, Kayala MA, Traoré B et al (2010) A prospective analysis of the Ab response to *Plasmodium falciparum* before and after a malaria season by protein microarray. Proc Natl Acad Sci 107:6958–6963. doi:10.1073/pnas.1001323107